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Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis globally and 
cause approximately 200,000 deaths and $64 billion in economic losses each year. 
HuNoVs are highly transmissible and pose unique challenges for research and 
detection. The most significant of these challenges is the historical lack of a reproducible 
cell culture system for propagating infectious HuNoVs. The recent development of 
HuNoV cultivation in human intestinal enteroids (HIEs) now enables detection of 
infectious HuNoV. However, this HIE approach has not been adapted for use in 
monitoring HuNoV in the environment. Identification of infectious HuNoVs from the 
environment can increase monitoring accuracy, enhance risk estimates, and help 
prevent outbreaks. The goal of this dissertation was to lay the groundwork for use of the 
HuNoV HIE cell culture method in environmental monitoring scenarios and ultimately to 
advance quantitative microbial risk assessments (QMRAs). My research documented 
that HIEs can be used to cultivate HuNoV recovered from fomites relevant to HuNoV 
transmission in health care settings.  A QMRA was then developed to model the risk of 
HuNoV illness for environmental service workers (ESWs) in healthcare settings caused 
by exposure from a single fomite contact in rooms with a HuNoV positive patient. ESWs 
face significant occupational health risks during HuNoV outbreaks and may also play an 
important role in transmitting the virus. The QMRA revealed that diarrheal events may 
drive fomite transmission of HuNoV. In sum, this dissertation provides a blueprint for 
using the HIE system to grow infectious HuNoVs recovered from the environment and 
presents a novel QMRA model that can be adapted and integrated with future measures 
to isolate and identify infectious HuNoV. This work fills important gaps in HuNoV 
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monitoring and risk assessment and provides approaches and tools to improve HuNoV 
detection, lead to more accurate predictions of health outcomes, and better evaluate 
control measures designed to reduce the HuNoV burden on human health. 
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CHAPTER ONE:  
Introduction 
Diarrheal illnesses remain a significant global health burden, causing 
approximately 1.6 million deaths per year, a third of which are in children under 
the age of five (1,2). The majority of acute gastrointestinal illnesses (AGI) are 
caused by human noroviruses (HuNoVs) (3). Each year, HuNoVs cause an 
estimated 685 million illnesses and cost the global economy $64.5 billion (3-5). 
Approximately 200,000 people die of HuNoVs annually, and about a quarter are 
children under the age of five (5). In the US alone, 1 in 20 people become 
infected with HuNoV each year and this high rate of illness leads to significant 
societal burdens. This includes direct strain on healthcare systems, loss of 
productivity and reduced quality of life due to illness, and rare, but severe, long 
term complications arising from chronic cases (6).  
 
HuNoVs are members of the Caliciviridae family and are thought to cause illness 
exclusively in humans (7). Typical symptoms of HuNoV infection are nausea, 
vomiting, and diarrhea which are typically of short-duration (2-3 days) and self-
limiting in immunocompetent hosts (7). Transmission of HuNoVs occurs through 
the fecal-oral route and these viruses are highly infectious (6,8). HuNoVs are 
stable in the environment for up to weeks or even months, are shed in large 
numbers by both symptomatic and asymptomatic infected hosts, and very few 
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virions are required for infection (9-13). HuNoVs encompass multiple viral strains 
that differ slightly in structure but retain basic similar characteristics (14). Namely, 
HuNoVs are small (~27nm diameter), spherical, non-enveloped viruses with a 
T=3 icosahedral structure formed by repeats of one major (VP1) and one minor 
(VP2) structural proteins (15). HuNoV genomes consist of single stranded 
positive sense RNA, ~7.7 kb long, and contain three open reading frames - 
ORF1 encodes nonstructural proteins, while ORF2 and ORF3 encode the 
structural proteins VP1 and VP2 (16).  
 
HuNoVs are classified by a genogroup and genotype number that relate to slight 
structural variations. The two main genogroups that cause human illness are one 
and two - represented as GI and GII, respectively (17,18). Genotype is 
represented by a number after genogroup and a range of genotypes cause 
illness, with new types continuously emerging as the virus evolves (19). A third 
level of HuNoV categorization is strain name, usually related to the geographic 
location of first isolation. For example, the main epidemic strain of HuNoV that is 
currently in global circulation is GII.4 Sydney - genogroup two, genotype four, 
strain Sydney (20,21).  
 
In addition to their high transmissibility, HuNoVs pose unique challenges for 
research and detection. The most significant of these challenges is the historical 
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lack of a reproducible cell culture system for propagating infectious HuNoVs 
(22,23). The first documented case of HuNoV was from an outbreak of AGI in a 
school in Norwalk, Ohio, USA in 1968 and the strain was identified four years 
later in 1972 (24). However, HuNoVs have remained resistant to in vitro culture 
for over four decades (25,26).  
 
The lack of a reproducible cell culture system for HuNoV had profound impacts 
on research and monitoring efforts (27,22,23). Molecular tools that detect the 
presence of HuNoV RNA remain the most common tool for identifying and 
working with HuNoVs (28). The most common of these molecular tools is reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) using primers 
and probes that target the ORF1-ORF2 capsid junction or the RNA dependent 
RNA polymerase in the viral genome (29). RT-qPCR offers many benefits for 
detecting HuNoVs - the method is relatively rapid to perform (3-4 hours), very 
sensitive, and easily quantifiable (30,31). The significant caveat to RT-qPCR and 
other molecular approaches for detecting HuNoVs is the inability to distinguish 
infectious particles from non-infectious segments of RNA (22). Extensive 
literature has been dedicated to understanding the relationship between 
molecular measurements of HuNoV RNA and the presence of actively infectious 
HuNoVs (32,22,33). Alternative methods that are thought to better approximate 
infectivity have been suggested, but besides inoculating human volunteers 
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(10,34), a reproducible cell culture remains the only way to confirm the presence 
of infectious HuNoV (35,32,36,37). 
 
In 2016, the first reproducible HuNoV cell culture system was developed (38). 
This represented a momentous stride in HuNoV research and opened the door 
for a slew of new ways to study HuNoVs. The HuNoV cell culture system uses 
human intestinal enteroids (HIEs) which are three-dimensional spheroids that 
recapitulate the epithelium of the human small intestine (38). HIEs are 
multicellular, differentiated, physiologically active cultures that contain all of the 
main intestinal epithelium cell types including LGR5+ stem cells, Paneth cells, 
enteroendocrine cells, enterocytes, and goblet cells (39-41). In particular, HIEs 
used to grow HuNoVs are from jejunal biopsies as this is thought to be the major 
area of HuNoV replication in the body (38). HIEs are established by isolating 
crypt cells from a human jejunal biopsy that can then produce multiple spheroids. 
HIEs are not immortal, but can be sequentially passaged and maintained for 
multiple months or even years (42,38,39).  
 
Infection of HIEs with HuNoVs requires breaking spheroids into a single cell 
suspension and seeding this suspension on a basement membrane to generate 
monolayers (42,38). These monolayers are differentiated to recapitulate mature 
enterocytes, enteroendocrine cells, and goblet cells, then HuNoV suspensions 
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are added directly to monolayers (43). HIE monolayers are not readily 
quantifiable as they do not form plaques or other easily identifiable signs of 
cytopathic effect that are used to quantify viruses in other cell culture systems 
(44,38,45). Instead, HIEs must be infected in duplicate and then viral RNA is 
extracted from one plate at one hour post infection (hpi), while the second plate 
grows for 72 hpi before viral RNA extraction (43). The RNA extracted at 1 and 72 
hpi is quantified with RT-qPCR and changes in HuNoV genome equivalents (GE) 
are compared between the two time points. An increase in GE is indicative of 
actively infectious HuNoVs (38). 
 
Though HuNoV cultivation in HIEs is a major scientific breakthrough, this system 
is subject to numerous limitations. HuNoV growth in HIEs can be highly variable 
both within and across strains (42,45). The need for RT-qPCR complicates the 
ability to obtain quantitative measures of growth from HIEs. Additionally, HIEs are 
extremely complex systems that require a significant level of training, labor, and 
monetary resources to establish and maintain (44,43). The reagents to test a 
single HuNoV sample in HIE culture cost approximately $36 and the entire 
process from start to finish requires a minimum of three weeks. These challenges 
with the HuNoV cell culture system affect all applications of the method. 
However, the drawbacks of the HIE system become significantly more 
pronounced when the goal is to use HIEs to attempt to grow the low titers of 
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HuNoV recovered from the environment, either for monitoring, risk assessment, 
or to test inactivation methods. 
 
Environmental monitoring of HuNoVs could be revolutionized by the development 
of the HIE cell culture method. The ability to identify infectious HuNoVs in the 
environment can help target areas for intervention, allow for more accurate 
testing of inactivation methods, and can improve risk assessments (46-48). Risk 
assessments, also referred to as quantitative microbial risk assessments 
(QMRA), are a valuable tool in translating microbial monitoring data into public 
health impacts. Briefly, QMRA consists of four steps that require identification of 
the hazards, precise description of exposure, quantification of dose-response, 
and integration of quantitative data to model risk values for an exposure scenario 
(49). HuNoV QMRAs have been significantly hampered by the lack of data on 
HuNoV presence and transmission (50-52). The HIE cell culture offers a new 
data source that could help improve QMRA and risk prediction for HuNoVs. 
 
The goal of this dissertation was to lay the groundwork for use of the HuNoV HIE 
cell culture method in environmental monitoring scenarios and ultimately in 
QMRAs. The steps taken to achieve this goal can be summarized in three 
primary research objectives: 
7 
 
1. Measure the impact of key experimental variables on HuNoV growth in 
HIE cells and establish a set of recommendations for moving forward with 
monitoring applications. 
2. Determine the conditions necessary to grow surface-recovered HuNoV 
in HIE cells and characterize recovery of infectious HuNoV. 
3. Develop a QMRA that can serve as a template for integrating HuNoV 
cultivation data in the future. 
 
Each research objective is presented as a standalone chapter that represents a 
manuscript in preparation for peer review. 
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Optimizing human intestinal enteroids for environmental 
monitoring of human noroviruses 
Katie N. Overbey, Nicholas C. Zachos, Caroline Coulter, Kellogg J. Schwab 
 
Abstract 
Human noroviruses (HuNoV) are the leading cause of gastrointestinal illness and 
environmental monitoring is crucial to prevent HuNoV outbreaks. The recent 
development of a HuNoV cell culture assay in human intestinal enteroids (HIEs) 
has enabled detection of infectious HuNoV. However, this complex approach 
requires adaptation of HIE to facilitate HuNoV replication from environmental 
matrixes.  Integrating data from 200 experiments, we examined six variables: HIE 
age, HIE basement membrane compounds (BMC), HuNoV inoculum processing, 
HuNoV inoculum volume, treatment of data below limit of detection (LOD), and 
cutoff criteria for determining positive HuNoV growth. We infected HIEs with 
HuNoV GII.4-Sydney positive stool and determined 1.4x103 genome equivalents 
per HIE well were required for HuNoV replication. HIE age had minimal effect on 
assay outcomes. LOD replacement and cutoff affected data interpretation, with 
lower values resulting in higher estimated HuNoV detection. Higher inoculum 
volumes lead to minimal decreases in HuNoV growth, with an optimal volume of 
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250uL facilitating capture of low concentrations of HuNoVs present in 
environmental isolates. Processing of HuNoV inoculum is valuable for 
disinfection studies and concentrating samples, but is not necessary for all HIE 
applications.  This work enhances the HuNoV HIE cell culture approach for 
environmental monitoring. Future HIE research should report cell age as days of 




Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis 
globally and cause approximately 200,000 deaths and $64 billion in economic 
losses each year (1,2). Due to high transmissibility and persistence, HuNoVs in 
the environment pose a significant infection risk which makes accurate 
monitoring crucial for prevention and control (3,4).  
 
Traditionally, HuNoVs resisted culture efforts (5) and could only be detected with 
molecular methods that measure viral RNA (6-10).  These approaches frequently 
use reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and 
values can be converted to a measure of HuNoV genome equivalents (GE) using 
an internal standard with a known amount of RNA (11,12). Though molecular 
approaches are fast, sensitive, and easily quantifiable, the detection of HuNoV 
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RNA is not necessarily indicative of infectious virus (13,14). Additionally, RT-
qPCR assays can be subject to reaction inhibition as a result of organic matter 
present in samples (15). 
 
The inability to measure infectious HuNoV virions can hamper public health 
interventions as the relationship between HuNoVs detected via RT-qPCR and 
infectivity in a human host is not clear (9). Several approaches to improve nucleic 
acid amplification correlation with viral infectivity have been reported (16-20).  A 
reproducible cell culture infectivity model remains the definitive way to confirm 
the presence of infectious HuNoV (8,9).  Identifying infectious HuNoV by cell 
culture can be a direct correlation to human health outcomes. An infectivity 
model presents the opportunity to develop more accurate risk assessments, 
predict health outcomes based on monitoring data, and conduct viral inactivation 
experiments that better capture true reduction of infectivity (21,22). 
 
An approach that has been successfully used to cultivate HuNoV is human 
intestinal enteroid (HIE) cell culture (23). HIEs, also termed “mini-intestines,” are 
three-dimensional polarized structures that recapitulate the human intestinal 
epithelium (24,25). For growth of HuNoV, crypt cells are isolated from a human 
jejunum biopsy to generate jejunal HIEs as the second section of the small 
intestine is considered the main site of HuNoV replication (26). HIEs require the 
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addition of growth factors, including Wnt3a, R-spondin, and Noggin, to stimulate 
the development of crypt cells into multi-cellular spheroids that contain the major 
cell types found in the human intestinal epithelium (24,27). HIEs mimic major 
aspects of normal intestinal epithelial physiology, including electron transport and 
cell lifespan, and demonstrate key pathophysiological responses to pathogen 
infection (28,25). 
 
HIEs are maintained as 3D cultures prior to processing the HIEs for infection with 
HuNoV (26,29). Preparation for infection involves disrupting the HIEs into a 
single cell suspension, subsequent seeding of cells as monolayers in 96 well 
tissue culture plates, and inducing differentiation by removal of Wnt3a, which 
leads to the development of mature absorptive enterocytes and secretory cells 
(26,25,29). These differentiated HIE monolayers can then be infected with 
HuNoV (26). The HIE method shows promise in bridging the gap between 
measurements of RNA and the presence of actively replicating HuNoV virions by 
mimicking the physiological processes of the gut (30,31,26).  
 
In HIEs, HuNoV growth is measured as the fold increase in HuNoV GE between 
1 and 72 hours post infection (hpi) (26). A cutoff value for fold-increase in GE can 
then be set to classify samples as positive or negative for replication of infectious 
HuNoV. The ability to culture HuNoV in vitro has important implications for 
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vaccine research, clinical detection, and testing inactivation methods 
(32,33,30,34,23,35-39). An important application of HIE cell culture is growing 
HuNoV recovered from food, water, air, and fomites. The isolation and detection 
of HuNoV RNA recovered from environmental isolates is frequently used to 
monitor cleaning efficacy and determine potential interventions that are needed 
to protect human health (40-43). However, environmental monitoring has 
different technical needs than other applications of the HIE system (44,45,10,46). 
First, quantitative values for infectious HuNoV need to be reproducible and 
meaningful. In monitoring applications, infectious HuNoV detection must be 
reflective of input HuNoV and samples with similar input should yield similar 
measures of infectious HuNoV (15,43). Second, qualitative cutoffs to determine 
positive versus negative samples must be robust and consistent. In monitoring, 
qualitative measures of presence/ absence are frequently used and these 
measures must accurately reflect underlying presence of HuNoV (44,43). And 
third, methodologies should be standardized to ensure comparable values across 
research groups (47). Choices of reagents, handling of HIE cells and HuNoV 
inoculum, and data interpretation and presentation should be done in a way that 
allows for ease of replication and comparison across studies (44,47).  
 
Refining the HIE cell culture method to address the needs of environmental 
monitoring is hindered by the complexity in maintaining and infecting HIEs with 
HuNoV (31,23). The HuNoV HIE culture method requires numerous reagents, 
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including specialized collagen matrix and growth media, multiple laborious steps, 
including manual trituration of cells, and significant financial investment (23).  
This study reports on key aspects for HuNoV cultivation in HIE with a focus on 
developing approaches for environmental samples. The generated data were 




Figure 1 outlines the method for growing human norovirus in HIE.  We measured 
infectivity of HuNoV isolated from norovirus-positive human stool samples in HIE 
using previously described methods (30,26). Six key experimental variables were 
addressed to examine impacts on HuNoV growth:  
HIE culture variables: 
1. HIE cell age 
2. BMC for seeding HIE monolayers 
HuNoV suspension variables: 
3. Processing method for HuNoV suspensions 
4. Volume of HuNoV suspension added to HIE 
Data processing variables: 
5. Handling of values that fall below the limit of detection (LOD) 




2.1 Human Norovirus Stool Samples & Processing 
We tested four HuNoV GII positive stool samples from adult and pediatric 
patients; samples were genotyped based on the capsid region (48) (Table 1). All 
samples were diluted to 10% in sterile phosphate buffered saline and filtered 
through a 0.45µm filter. A subset of the pediatric GII.4 Sydney stool sample was 
further processed with one of three methods: Vertrel XF (DuPont, Wilmington, 
DE); Vertrel XF plus 0.45µm filtration; or Vertrel XF, 0.45µm filtration, and 
sucrose cushion ultracentrifugation, as previously reported (49).  Briefly, equal 
parts 10% stool filtrate and Vertrel XF were homogenized on ice and the 
emulsified mixture was centrifuged for 15 min at 4000 x g; supernatant was 
recovered and used as “Vertrel” labeled stool suspension. A subset of Vertrel 
suspension was then passed through a 0.45 μm filter and resulted in “Vertrel and 
filtered” stool suspensions. The highest processing step involved purification of 
Vertrel and filtered suspensions with sucrose cushion ultracentrifugation. The 
Vertrel and filtered HuNoV suspension was overlaid on a sterile-filtered 20% 
sucrose solution in an Ultraclear centrifuge tube (Beckman, Brea, CA) and 
centrifuged for 3 h at 95,000 x g; this process was repeated using an additional 
Vertrel and filtered HuNoV suspension before suspending the resulting pellet.  
The final suspension was defined as a “sucrose” HuNoV suspension. Samples 
were portioned and immediately stored at -80°C until time of testing. Portions 
were used for a maximum of three individual experiments and were limited to no 
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more than three freeze-thaw cycles.  
 
2.2 Human Intestinal Enteroid Culture 
We maintained a secretor-positive jejunal HIE culture (J2 line), kindly provided by 
Mary Estes (Baylor College of Medicine, Houston, TX), as undifferentiated three-
dimensional (3D) (i.e. spheroid) cultures. This line has been previously used to 
grow HuNoV and human rotavirus (26,28). Human IntestiCult media (STEMCELL 
Technologies Inc., Vancouver, Canada) was used as complete media with 
essential growth factors to propagate HIEs; complete media without growth 
factors (CMGF-) was prepared as previously described (26). Cultures were 
maintained at 37°C in 5% CO2 in 24-well cell culture plates. After 7 days of 
growth, 3D cultures were either split 1:2, archived in liquid nitrogen (LiN2), or 
dissociated to a single cell suspension and plated 1:2 as an undifferentiated 
monolayer in a 96-well cell culture plate. HIE monolayers were seeded on 
Matrigel (Corning, Corning, NY) or human Collagen IV (Sigma-Aldrich, St. Louis, 
MO), and grown for two days in IntestiCult supplemented with 10 µmol/L Y-
27632. Monolayers were subsequently differentiated for 5 days prior to infection 
with media prepared by Johns Hopkins Conte NIH/NIDDK Digestive Diseases 
Basic and Translational Research Core Center, as previously described (50,28). 
Cell age was measured in terms of passage number, days of continuous growth, 
and length of time archived in LiN2. Passage number was not reflective of HIE 
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freeze-thaw cycles. Days of continuous growth represent the number of days 
between removal of HIEs from LiN2 archive and subsequent infection with virus. 
In some instances, propagated HIEs were obtained directly from other 
laboratories within Johns Hopkins University. In these instances, due to the lack 
of propagation history, receipt of HIE cultures by our lab personnel were 
considered day 1 of growth.  
 
2.3 Human Norovirus Infection Experiments 
Confluent HIE monolayers were infected apically after 5 days of differentiation, in 
duplicate, with processed HuNoV virus supplemented with 500 µM of 
glycochenodeoxycholic acid (GCDCA; Sigma-Aldrich, St. Louis, MO). After 1 
hour of incubation at 37°C in 5% CO2 to allow viral attachment, the supernatant 
was removed and monolayers were washed three times with CMGF-. For each 
set of infections, after the third wash, one monolayer was immediately frozen at -
80°C and the second was grown at 37°C in 5% CO2 for 72 hours post infection 
(hpi). Following the 72-hour incubation, the supernatant and monolayer cells 
were frozen at -80°C. We extracted RNA from 1 hpi and 72 hpi monolayer cells 
and supernatants with the Direct-zol RNA miniprep kit (Zymo Research, Irvine, 
CA). HuNoV RNA copies were measured with RT-qPCR using the QuantiTect 
Probe RT-PCR Kit (Qiagen, Hilden, Germany) with COG2 primers and the 




In order to calculate a quantitative HuNoV GE we developed a standard curve 
using in vitro RNA transcripts derived from plasmid pNoV/MD145, kindly provided 
by Michael Kulka (FDA, Silver Spring, MD, USA), which contained a full-length 
synthetic cDNA copy of a HuNoV GII strain (12). Based on 14 runs of seven 
dilutions in duplicate, the RT-qPCR limit of detection (LOD) was determined to be 
44.3 viral GE/ 5uL, as calculated using the discreet threshold method (47). 
 
2.4  Statistical Analyses 
Statistical analyses were performed in Stata 13 and R 3.6.1 (StataCorp, 2013; R 
Core Team, 2019). We use the term HuNoV growth to refer to the fold increase 
in HuNoV GE between 1 and 72 hpi in HIEs. Unless otherwise stated, samples 
were considered negative for infectious HuNoV if the fold increase was less than 
five. Values below the RT-qPCR LOD (44.3 GE/ 5uL) were replaced with the 
LOD value unless stated otherwise.  
 
The Kruskal-Wallis one-way ANOVA on ranks test (KW) was used to examine 
the relationship between single input variables and fold increase as a continuous 
outcome; the Kruskal-Wallis test was chosen as the data were non-parametric. 
Age of HIEs was treated as a categorical variable due to the pseudo-continuous 
nature of age values. HIE passage numbers were aggregated to categories of 
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20-29, 30-39, 40-49, and 50-59; HIE days of growth were aggregated to 0-49, 
50-99, 100-149, and 150-199; HIE days in archive were aggregated to 0-99, 100-
199, 200-299, and 300-399. For many variables, we aimed to control for input 
virus when measuring statistical differences. To achieve this, significance was 
tested with binomial logistic regression (BR) for binary outcomes and linear 
regression (LR) for continuous outcomes. All continuous outcomes were log 
transformed prior to regression analysis. 
 
3 Results 
3.1 Selection of HuNoV Strain 
We screened four 10% stool suspensions containing HuNoV to determine their 
ability to replicate in HIEs (Table 1). Two samples replicated in the HIE system – 
a pediatric GII.4 Sydney and an adult GII.4-16 recombinant (data not shown). 
The increase in HuNoV GE between 1 and 72 hpi for the two virus strains is 
shown in Figure 2. No significant difference was observed in increase in HuNoV 
at 72 hpi (KW p=0.29). Ten of 38 GII.4-16 recombinant experiments were 
positive for infectious HuNoV, while 18 of 33 GII.4 Sydney experiments were 
positive. Due to the lower detection rate of infectious norovirus in GII.4-16 
recombinant experiments, the pediatric GII.4 Sydney virus was used in all 




3.2 Age of HIE Cells 
Three measures were used to examine the relationship between age of HIE cells 
and HuNoV growth (Figure 3). When controlling for input virus, HIEs at passage 
40 to 49 were associated with a 2% increase in odds of detecting HuNoV, 
compared to passage 20-29 (BR p=0.04); no other passage category was 
associated with an increase in detecting infectious HuNoV (BR p-values>0.05).  
When HIE age was measured as days of growth, there was no association with 
detection of infectious HuNoV (BR p-values>0.9). Similarly, no association was 
observed between category of days archived in LiN2 and qualitative detection of 
infectious HuNoV (BR p-values>0.05). HuNoV growth was observed at the 
maximum value for all three measures of age: passage 58, 187 days of 
continuous growth, and 334 days archived in LiN2.  
 
3.3 Basement Membrane Compound 
The relationship between HuNoV growth and HIE monolayer BMC is shown in 
Figure 4. Fifty-four percent (75/140) of Matrigel seeded HIE monolayers were 
positive for infectious HuNoV, while 32% (7 of 22) of collagen experiments were 
positive. The proportion of samples positive for infectious HuNoV were not 
significantly different between the two membranes when controlling for input virus 
(BR p=0.1). However, when controlling for input virus, HIE monolayers seeded 
with Matrigel had a significantly higher measured fold increase in HuNoV GE 
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between 1 and 72 hpi, compared to HIE monolayers seeded with Collagen IV 
(LR p = 0.03). 
 
3.4 Titer of Input HuNoV 
Prior to investigating the role of HuNoV viral suspension variables in growth in 
HIEs, we measured the relationship between input HuNoV GE and measured 
growth for HIEs using 100μL inoculation volumes of 0.45μm filtered virus 
(“baseline” experiments denoted with grey points in Figures 5 and 6). An 
increase in input HuNoV was significantly associated with a higher likelihood of 
detecting infectious virus (BR p=0.03) and with an increase in HuNoV growth as 
measured by fold increase (KW p = 0.03). No growth of HuNoV was observed at 
input values below 1.4 x 103 GE/ well (data not shown).  
 
3.5 HuNoV Inoculum Processing  
The impact of different viral inoculum processing steps on HuNoV growth, 
compared to baseline experiments, is shown in Figure 5. No significant 
association was observed between proportion of samples positive for HuNoV 
across the three additional processing steps when compared to baseline (BR 
p>0.3). When controlling for amount of input HuNoV, there was no association 




3.6 HuNoV Inoculum Volume 
The impact of infecting HIEs with different volumes of HuNoV suspension on 
HuNoV growth are shown in Figure 6. Compared to a 60% positive detection rate 
for 100μL samples (70/116), the detection rate was 50% for both 200μL (6/12) 
and 250μL (2/4) infections and 75% for 300μL infections (6/8). When controlling 
for amount of HuNoV GE, HIEs inoculated with 200μL of HuNoV stool 
suspension had reduced odds of positive detection of infectious HuNoV, 
compared to 100μL (BR p=0.009).  However, volumes higher than 200μL were 
not associated with decreased detection of HuNoV (BR p-values>0.1).  
 
3.7 Limit of Detection 
The three methods for replacing values below the limit of detection resulted in a 
significant difference in proportion of samples positive for HuNoV (BR p<0.0001). 
The highest percent detection of infectious HuNoV was observed when below 
LOD values were replaced with half of the LOD (61%, 71/116), followed by 
replacement with the LOD (60%, 70/116), and then dropping values below the 
LOD (33%, 38/116). When only positive experiments were then considered in 
each category, fold increase in HuNoV GE in HIEs across the three methods was 




3.8 Positive Fold Cut-Off 
We examined the impact different cut-off values for fold increase in HuNoV GE 
between 1 and 72 hpi to determine if samples contained infectious HuNoV. Three 
cut-off values were selected - greater than or equal to 1, 5 (baseline), and 10 
(Figure 8). The percent of samples positive for infectious HuNoV were not 
significantly different across the three cut-off values and ranged from 65% for a 
fold cut-off of ≥1 (75/116) to 57% for a fold cut-off of ≥10 (68/116) (BR p≥0.3).  
 
To examine how differences in fold cutoff may affect data interpretation, we 
analyzed the relationship between fold increase for positive samples and the 
amount of input virus, as this association is well documented in the literature. For 
each fold cutoff, there was a significant association between input HuNoV and 
fold increase for positive experiment as measured by the Kruskal-Wallis one-way 
ANOVA on ranks test (p-values<0.03). 
 
4 Discussion and Conclusions 
The ability to grow HuNoV in HIEs is a significant advancement for HuNoV 
research (31,23). The HIE system enables the definitive detection of infectious 
HuNoV, which has a profound impact on vaccine research, clinical monitoring, 
and environmental detection for HuNoV (32,33,30,34,23,35-38,52,39). Of 
particular interest is environmental monitoring applications of the HIE cell culture 
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system for HuNoV. Environmental presence of HuNoV is frequently used to 
measure efficacy of interventions and assess public health risk (40-43). 
Monitoring applications can greatly benefit from the integration of cell culture to 
detect infectious HuNoV (53). This would allow for more accurate predictions of 
health outcomes and could prevent the unnecessary expense of resources to 
treat environmental sources that may contain HuNoV RNA but no actively 
infectious HuNoV. 
 
To this end, we sought to further develop and codify the HIE cell culture system 
to facilitate HuNoV environmental monitoring applications. Methodological details 
can vary across research groups and include components of the HIE culture 
itself, handling of the HuNoV suspensions to be tested, and data processing 
decisions that have yet to be systematically evaluated (Table 2). We selected 
some of these methodological details to examine the effects on qualitative and 
quantitative measures of infectious HuNoV and translated these data into a list of 
recommendations (Table 3). For the HIE system, qualitative measurements 
describe the number of samples considered positive for infectious HuNoV, while 
quantitative measurements reflect the increase in HuNoV GE in the HIE system, 
usually represented as fold increase. 
 
Prior to testing experimental variables, we tested four HuNoV positive stool 
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samples to identify the best candidate for growth in HIEs. The most successful 
growth was from a pediatric stool sample that contained HuNoV GII.4 Sydney. 
This is consistent with prior reports that GII viruses and stool from pediatric 
patients grow best in the HIE system (30,23). 
 
4.1 HIE Culture Variables 
The first HIE cell culture variable we examined was cell age. Previous work with 
HuNoV in HIEs either did not report this information or included HIE age as 
passage number, which represents the number of times a line has been split 
(32,54,30,34,26,35,37,38,52,39). We analyzed HIE age data three ways: as cell 
line passage number, as days of continuous growth in the lab prior to infection 
with HuNoV, and as number of days the line had been archived in LiN2 (Figure 
3). We found that we were able to observe successful growth up to passage 58, 
which is significantly higher than previous studies that report a maximum 
passage of 31 (54,30,52). An increase in passage number was only associated 
with an increase in the percent of samples positive for HuNoV for HIEs at 
passage 40-49; while no relationship was found for days of continuous growth or 
days archived. This discrepancy illustrates that passage number may not be 
ideal as a standalone measure of cell age. Each passage equates to roughly one 
week, but passage number is not directly tied to any age, as cell lines can be 
frozen and unfrozen without any change in passage number. The inconsistent 
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association between cell age and HuNoV replication has been observed by 
others where a 3 log10 difference in HuNoV replication in HIEs across a four-year 
period was observed, but no apparent relationship between time cultured and 
resulting HuNoV replication (23). 
 
The second HIE associated variable we examined was the BMC used to stabilize 
monolayers seeded onto 96 well tissue culture plates. BMCs are comprised of 
protein matrices that are deposited beneath epithelia and form sheets that 
provide mechanical stability and can influence cell shape and proliferation (55). 
There is no consensus in the literature on choice of BMC for HIEs to cultivate 
HuNoV. Previous methods for growing HuNoV in HIEs report the use of either 
Collagen IV (32,30,34,38,52,29) or Corning Matrigel (26,35,37). We found that 
the two different BMCs resulted in similar qualitative measures of infectious 
HuNoV (Figure 4), but when accounting for amount of input virus, more HuNoV 
growth was observed in HIE monolayers seeded with Matrigel. A low sample size 
was used for Collagen IV experiments, compared to Matrigel, as we switched all 
experiments to Matrigel after observing successful growth. As such, it is possible 
that the two methods are comparable. However, we maintain our suggestion of 
Matrigel as a BMC for environmental monitoring applications because per 
experiment, the cost of Matrigel is about 30% lower than that of Collagen IV, and 
cost reduction is an important consideration to increase the feasibility of HIEs for 




4.2 HuNoV Infection Inoculum Variables 
Multiple research groups have determined that higher input viral titer leads to 
more successful growth of HuNoV in HIEs and we confirm these findings (30,23). 
Our work showed that the minimum HuNoV dose required to measure growth in 
HIEs is 1.4 x 103 GE/ well (Figures 5 and 6), consistent with previous reports 
(30).  
 
The first HuNoV inoculum variable we studied was processing of HuNoV stool 
prior to infection in HIEs. Currently, no variability in processing method for 
HuNoV stool is observed in the literature - all studies report the use of 10% stool 
filter through either a 0.22μm or a 0.45μm filter (32,54,30,26,23,52,39,29). Our 
interest in HuNoV stool suspension processing was driven by data that indicates 
more highly processed samples, with less organic load, are desirable for 
disinfection studies (49). As disinfection studies are an important application of 
the HIE culture system, it was important to test alternative methods for 
processing HuNoV stool samples (30). A reduction in organic load in viral 
inoculum has an important effect on disinfection kinetics and allows for a more 
accurate measure of both disinfectant residual and true efficacy of the 
disinfectant on HuNoV (56,57). Additionally, HuNoV recovered from the 
environment is likely to be very low titer which necessitates concentration 
37 
 
methods (58-60). However, historical efforts to cultivate HuNoV indicated that 
higher purity samples may actually resist growth due to the absence of 
necessary components present in stool (5). Our results show that this is not the 
case and that high purity HuNoV samples processed with a combination of 
Vertrel XF, additional filtration, and/ or sucrose cushion ultracentrifugation do not 
replicate differently in HIEs.  
 
We were also interested in the volume of HuNoV stool suspension that was used 
to inoculate HIE monolayers. Previous HuNoV HIE cell culture work consistently 
used 100μL of infection volume, or did not report this variable at all 
(32,54,30,34,26,37-39,29). Environmental samples are frequently low titer and 
the ability to test higher volumes in HIE culture may have value in improving 
detection of these types of samples (58,60,10). We tested infection volumes of 
200μL, 250μL, and 300μL (maximum volume of well) and found a slight decrease 
in detection of infectious HuNoV when using 200μL, but no association for the 
other volumes (Figure 6). It is important to note that statistical measures for 
volume are likely subject to errors with small sample sizes in higher volume 
categories, compared to baseline 100μL tests. The 300μL infection experiments 
had a higher rate of detection (75%) of infectious HuNoV compared to 100μL 
experiments (60%). We suggest the use of a higher infection volume for 
environmental monitoring because the ability to test larger sample volumes can 
allow for improved detection in low titer samples. A final infection volume of 
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250μL is suggested because 300μL is close to the maximum capacity of wells 
and could lead to spills, sample loss, or contamination. 
 
4.3 Data Processing Variables 
Finally, we investigated how different data processing decisions impact results 
from growing HuNoV in HIEs. The first of these decisions was the method used 
to replace data points that were below the RT-qPCR assay LOD. Environmental 
monitoring is likely to produce many values that fall below the LOD of the RT-
qPCR assay due to low viral titer in the environment (40,58-60). Previous 
literature has indicated that the choice of LOD handling can significantly impact 
outcomes, but no consensus on the most appropriate method exists in the 
literature (61,62). We chose to investigate methods that replaced below LOD 
values uniformly, either with the LOD value, half the LOD value, or with zero, 
effectively dropping the sample. We did not investigate any methods for 
predicting below LOD values with a model as this may be too computationally 
intense for regular monitoring applications (61). Based on our results, we do not 
suggest dropping below LOD values as this can lead to a significant 
underestimation of infectious HuNoV. However, the difference between using the 
LOD value versus half the LOD is less clear and resulted in similar measures of 
HuNoV. This relationship warrants further investigation and until stronger 
rationale is available, we suggest explicitly stating the LOD replacement method 
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in the Methods when using HIEs for HuNoV detection and analysis. 
 
The second data handling decision that we investigated was the choice of cutoff 
for fold increase in HuNoV GE between 1 and 72 hpi to determine if a sample 
contained infectious HuNoV. Fold cutoff values vary in the literature from greater 
than or equal to 1 up to 10, with some studies not reporting a cutoff at all and 
presumably including all samples with a positive fold increase (54,30,34). For 
most of this work we chose a positive fold cutoff of greater than or equal to five 
as this was the middle of previously reported values. We found that the choice of 
fold cutoff did not lead to statistical differences in the percent of samples 
identified as positive for HuNoV (Figure 7). However, final percent positive 
samples ranged by 8% between the lowest cutoff, ≥ 1, and the highest cutoff, ≥ 
10.  This difference could be significant in monitoring scenarios as high cutoff 
values could miss up to 8% of true positives, while low cutoff values could lead to 
more false positives.  
 
To examine how differences in fold cutoff may affect data interpretation, we 
analyzed how different cutoff values impacted the relationship between fold 
increase for infectious HuNoV positive samples and the amount of input virus, as 
this association is well documented in the literature (30,23). We found that for all 
three values of fold cutoff there was a statistically significant positive association 
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between viral input titer and measured fold increase. This indicates that differing 
fold cutoffs may affect qualitative measures of infectious HuNoV, but likely do not 
alter measured associations between variables. For environmental monitoring 
applications of the HIE system, the lowest fold cutoff will result in data that is the 
most protective of human health, but may lead to the decision to dedicate limited 
resources to addressing what ultimately may be false positive measures of 
infectious HuNoV. Due to this existing uncertainty, the use of multiple fold cutoffs 
remains ideal to account for potential false positives and negatives.  
 
This work addressed multiple methodological challenges in growing HuNoV 
using an HIEs approach, with specific attention towards applying the method to 
growing HuNoV recovered from the environment. Accurate measurement of 
infectious HuNoV in the environment, including food, water, and fomites, is a 
crucial first step in improving risk assessments for HuNoV infections in various 
settings. Additionally, these methodological refinements also improve the use of 
the HIE system for growing HuNoV samples that have been subject to 
inactivation or disinfection methods. Recommendations from this work (Table 3) 
serve as a foundation for future application of the HIE system to measuring 
infectious HuNoV recovered from the environment. These recommendations can 
guide future studies and form a blueprint for continued improvement of the 
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Table 2.1 Human norovirus (HuNoV) positive fecal samples tested for replication 
in human intestinal enteroid (HIE) monolayers  
HuNoV 
Genotype 
RNA copies/ 100µL  
Undiluted Stool 
Suspension 





2.0 x 107 Adult Jan 2017 
GII.4 Sydney 3.22 x 107 Pediatric Jan 2018 
GII.2 6.43 x 106 Adult Jan 2017 
GII.4 Sydney 6.02 x 104 Adult Dec 2017 











Table 2.2 Summary of experimental variables investigated for their impact on human norovirus (HuNoV) growth in 
human intestinal enteroids (HIEs)  
 
Variable Description 
Options for Handling or Addressing 
Variable 
Treatment of Variable in Previous 
Literature 
    
Age of HIE 
cells 
Age of HIE cells used 
to seed monolayers 
for HuNoV growth 
1. Report passage number which 
reflects how many times an HIE line 
has been split 
2. Report days of continuous cell 
growth, independent of passage 
number 
3. Report data related to archiving of 
HuNoV in liquid nitrogen; either as 
number of freeze-thaw cycles or 
amount of time frozen 
Most studies do not provide 
information on HIE cell age 
(32,34,26,35,37-39) and those 
that do only report passage 
number, with growth occurring in 
up to passage 30 (54,30,52) 




Media used to seed 
HIEs as a monolayer 
prior to HuNoV 
infection 
1. Corning Matrigel 
2. Collagen IV 
Previous methods for growing 
HuNoV in HIEs report the use of 
both Collagen 
(32,30,34,38,52,29) and Matrigel 
(26,35,37); no explanation is 










for HuNoV positive 
stool suspensions 
prior to HIE infection 
1. Prepare 10% stool suspension and 
filter through a 0.45 µm or 0.22µm 
filter 
2. Use further processing steps, such 
as Vertrel XF or sucrose cushion 
centrifugation, that concentrate 
samples and reduce organic matter 
Most studies use 0.45 µm or 




    
Infection 
Volume 
Volume of HuNoV 
positive stool 
suspension added to 
each monolayer well 
1. Infect with the standard volume 
from initial HIE reports: 100 µL 
2. Increase the volume to test more 
sample, up to the maximum well 
volume of 300 µL 
Most studies report using 100µL 
infection volumes 
(54,30,37,39,29); while some do 
not provide this information 
(32,34,26,38) 
    
LOD 
Handling 
Method for handling 
data that falls below 
the RT-qPCR limit of 
detection (LOD) 
1. Drop all values below the LOD 
2. Replace all LOD values with half the 
LOD or with the value of the LOD 
itself 
Below LOD values are most 
frequently replaced with half of 
the LOD (54,30,23,37) or a 
method for handling below LOD 
values is not stated (32,38,52,39) 
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Fold Cutoff Fold change in 
HuNoV genome 
equivalents (GE) 
between 1 and 72 
hours post infection 
(hpi) in HIEs used to 
identify positive 
samples 
A range of numbers can be selected for 
this value 
Reported fold cutoffs include >1 






Table 2.3 Recommendations for codifying different types of experimental variables for studies that use human 
intestinal enteroids (HIEs) to grow human norovirus (HuNoV) 
 
Experimental Variables Primary Recommendations Secondary Recommendations 
HIE Cell Culture   
− Age of HIE cells − Report HIE age as days of 
continuous growth between date 
of pulling HIE line from archive in 
LiN2 and date of infection with 
HuNoV 
− Record age of HIE information 
as passage number, days of 
continuous growth, and days 
archived 
− Examine the relationship 
between each age measure and 
resulting outcomes 
− Basement membrane 
compound (BMC) used to seed 
HIE monolayers 
− State BMC used and keep 
approach consistent throughout 
research project  
− The use of Matrigel for growth is 
comparable or better than 
Collagen IV and cost per sample 
is lower 
HuNoV Stool Suspension   
− Stool processing method − 0.22 or 0.45 µm filtered 10% 
stool suspension is appropriate 
for non-disinfection applications 
of HIEs 
− If organic demand needs to be 
minimized (e.g. evaluating 
chemical disinfection), sucrose 
− If higher HuNoV titer is required, 
the use of Vertrel XF or sucrose 
cushion ultracentrifugation 




should be used 
− Infection volume added to HIEs − For general application, 100µL 
inoculation volume is appropriate 
− For environmental monitoring 
applications where HuNoV titer 
may be low, a volume of 250µL 
is advisable 
− Run replicates of the same 
samples with different volumes 
to compare HuNoV replication 
Data Processing   
− Replacement method for below 
LOD values 
− Clearly state the assay LOD and 
indicate the number of samples 
that fell below this value 
− Do not drop data below the LOD, 
replace with either half the LOD 
or the LOD 
− Examine the effects that different 
LOD replacement values have 
on final data interpretation 
 
− Choice of GE fold cutoff for 
identifying samples with 
infectious HuNoV 
− State the fold cutoff used to 
determine if samples were 
positive for infectious HuNoV 
− Clearly identify when only 
positive samples are included in 
tables and figures 
− Analyze data with multiple fold 
cutoff values to identify impacts 







Figure 2.1 Method for growing human norovirus in human intestinal enteroids 
 




Figure 2.2 Human norovirus growth in human intestinal enteroids for two virus 
strains 
 
Human norovirus (HuNoV) growth as measured by increase in HuNoV genome 
equivalents (GE) between 1 and 72 hours post infection (hpi) in human intestinal 
enteroids (HIEs) for two virus strains: GII.4 Sydney (N = 18) and GII.4-16 
Recombinant (N = 10). Data only includes experiments with positive detection of 
infectious HuNoV (fold change ≥5) and dashed line indicates assay limit of 




Figure 2.3 Effect of human intestinal enteroid age on human norovirus growth using different growth measures 
 
PANEL A PANEL B PANEL C 
   
 
Human norovirus (HuNoV) growth as measured by increase in HuNoV genome equivalents (GE) between 1 and 72 
hours post infection (hpi) in different ages of human intestinal enteroids (HIEs). Data only include experiments with 
positive detection of infectious HuNoV (fold change ≥5) and the dashed line indicates assay limit of detection 
(LOD); error bars indicate standard error of the mean. Panel A represents HIE age as passage number ranging 
from 20-29 (N = 1), 30-39 (N = 23), 40-49 (N = 35), and 50-59 (N = 6). Panel B represents HIE as days of 
continuous growth ranging from 0-49 (N = 6), 50-99 (N = 21), 100-149 (N = 17), and 150-199 (N = 20). Panel C 
represents HIE as the number of days cells were archived in liquid nitrogen and ranged from 0-99 (N = 21), 200-
299 (N = 2), and 300-399 (N = 8) 
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Figure 2.4 Human norovirus growth in human intestinal enteroid monolayers 
seeded with two different basement membrane compounds  
 
 
Human norovirus (HuNoV) growth as measured by increase in HuNoV genome 
equivalents (GE) between 1 and 72 hours post infection (hpi) in human intestinal 
enteroid (HIEs) monolayers for two basement membrane compounds: Corning 
Matrigel (N = 75) and Collagen IV (N = 7). Data only include experiments with 
positive detection of infectious HuNoV (fold change ≥5) and dashed line indicates 




Figure 2.5 Relationship between initial dose of human norovirus and resulting 
growth in human intestinal enteroids for four viral inoculum processing methods 
 
Inoculum of human norovirus (HuNoV) added to human intestinal enteroids 
(HIEs) and resulting HuNoV growth as measured by fold increase in HuNoV 
genome equivalents (GE) between 1 and 72 hours post infection (hpi) for four 
viral inoculum processing methods. Grey points indicate baseline experiments. 
Data only include experiments with positive detection of infectious HuNoV (fold 
change ≥5); assay limit of detection was 886 GE/ well. 
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Figure 2.6 Relationship between initial dose of human norovirus and resulting 
growth in human intestinal enteroids for four input volumes of viral inoculum 
  
Inoculum of human norovirus (HuNoV) added to human intestinal enteroids 
(HIEs) and resulting HuNoV growth as measured by fold increase in HuNoV 
genome equivalents (GE) between 1 and 72 hours post infection (hpi) for four 
volumes of viral inoculum. Grey points indicate baseline experiments. Data only 
include experiments with positive detection of infectious HuNoV (fold change ≥5); 
assay limit of detection was 886 GE/ well.  
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Figure 2.7 Effect of value used to replace data below the limit of detection for 
human norovirus growth in human intestinal enteroids 
  
Human norovirus (HuNoV) growth as measured by increase in HuNoV genome 
equivalents (GE) between 1 and 72 hours post infection (hpi) in human intestinal 
enteroid (HIEs) monolayers for three methods of replacing below limit of 
detection (LOD) values – replacement with the LOD value (lightened bar denotes 
baseline experiments, N=70), replacement with half of the LOD (N=71), and 
dropping values below the LOD (N=38). Data only include experiments with 
positive detection of infectious HuNoV (fold change ≥5); error bars indicate 




Figure 2.8 Effect of varying the fold cutoff of HuNoV genome equivalents 
between 1 and 72 hours post infection for identifying human intestinal enteorid 
experiments that were positive for infectious human norovirus  
  
Number of experiments that were considered positive for infectious human 
norovirus (HuNoV) in human intestinal enteroids (HIEs) for three different fold 
cutoffs -≥1, ≥5 (lightened bar denotes baseline experiments), and ≥10. Proportion 
of experiments positive for infectious HuNoV was not significant across the three 
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CHAPTER THREE:  
Recovery of infectious HuNoVs from fomites via 
replication in intestinal enteroids  
Katie N. Overbey, Nicholas C. Zachos, Caroline Coulter, Joseph Jacangelo, 
Kellogg J. Schwab 
Abstract 
Contamination of fomites by human norovirus (HuNoV) can initiate and prolong 
outbreaks. Fomite swabbing is necessary to predict HuNoV exposure and target 
interventions. Historically, swab-recovered HuNoV is measured by molecular 
methods that detect RNA but not infectious HuNoV. The recent development of 
HuNoV cultivation in human intestinal enteroids (HIEs) now enables detection of 
infectious HuNoV. It is unknown if the swabbing process and swab matrix will 
allow for cultivation of fomite-recovered HuNoV. We used HIEs to culture swab-
recovered HuNoV from experimentally infected surfaces – a hospital bed tray 
(N=32), door handle (N=10), and sanitizer dispenser (N=11). Each surface was 
swabbed with macrofoam swabs premoistened in PBS plus 0.02% Tween80. 
Swab eluate was tested for infectious HuNoV by cultivation in HIE monolayers. 
Infectious HuNoV can be recovered from surfaces inoculated with at least 105 
HuNoV genome equivalents/ 3cm2. In total, 57% (N=53) of recovered swabs 
contained infectious HuNoV detected by HIEs. No difference in percent positive 




fomite swabbing can be combined with the HIE method to cultivate infectious 
HuNoV from the environment filling a significant gap in HuNoV detection. 
Identification of infectious HuNoVs from swabs can increase monitoring 
accuracy, enhance risk estimates, and help prevent outbreaks. Currently, high 
titers of HuNoV are required to measure HuNoV growth in HIEs and the HIE 
system precludes absolute quantification of infectious viruses. However, the HIE 
system is capable of providing a binary indication of infectious HuNoV which 
enhances existing detection methods. 
 
1 Introduction 
Contamination of fomites by human norovirus (HuNoV) is a significant public 
health threat that can initiate and prolong outbreaks (1-4). Swabbing of fomites is 
an important approach to elucidating exposure patterns (5-9).  Historically 
HuNoVs recovered from fomites have been detected by recovery of viral RNA 
with subsequent detection by reverse transcription-quantitative PCR (RT-qPCR).  
The advent of novel HuNoV culture methods offer new ways to fill important 
HuNoV knowledge gaps (10).  
 
HuNoVs are the leading cause of acute gastroenteritis globally and cause 
significant health and economic burdens (11). Approximately 200,000 people will 




billion annually (12,13). HuNoV can be transmitted in a wide range of settings, 
including healthcare facilities, schools, and food service facilities (14-17) 
 
HuNoV is spread through the fecal-oral route and virus transmission occurs from 
person-to-person contact, through aerosolized droplets, and from contact with 
contaminated fomites. In many community settings, fomite-based transmission is 
of particular concern due to long environmental stability of virus particles and low 
viral doses required for infection (18). There is evidence that fomites can initiate 
HuNoV outbreaks as well as lead to longer, more severe outbreaks (1-4). 
In light of the important role of fomites in HuNoV transmission, numerous efforts 
have been undertaken to isolate and quantify HuNoV on environmental fomites. 
Swabbing is required to recover HuNoV from fomites and is used extensively in 
HuNoV outbreak investigations (19,20). Additionally, fomite swabbing is used to 
identify environmental HuNoV contamination outside of outbreaks as a means to 
prevent transmission, monitor control efforts, and understand epidemiologic 
trends (5-9). Swabs collected from the environment also contribute significantly 
to the knowledge base necessary to conduct HuNoV risk assessments (21-23).  
Fomite swabbing is also an important laboratory technique for identifying efficacy 
of cleaning and disinfection protocols for HuNoV (24). 
 




imperfect, with previous reports of low and inconsistent recovery of both HuNoV 
and other pathogens of human health significance (25) (26-28,9,23). A number of 
studies have also aimed to identify the most effective methods for swab recovery 
of HuNoV. Though no method is 100% effective, polyurethane foam swabs pre-
moistened in PBS with Tween80 appear to have relatively consistent success in 
recovering HuNoV (29,28,25). The inconsistency in swabbing literature is due to 
the complexity required in development of a swabbing protocol. Researchers 
must choose swab material, buffer composition, surface type, recovery method, 
and detection method in order to balance efficient viral recovery with logistical 
considerations such as short sampling time (25).  
 
Once HuNoV is recovered from swabs, the most common detection method is 
identification of HuNoV RNA by RT-qPCR. Molecular detection of HuNoV is 
necessitated by the historical inability to culture HuNoV in any known cell models 
(30,10). Molecular methods remain popular due to their high sensitivity, ease of 
use, and ability to provide robust quantification (31,32). However, molecular 
methods are unable to distinguish infectious HuNoV particles from inactivated 
RNA (32). The absence of clear data on HuNoV particle infectivity hampers risk 
assessments, environmental monitoring, and laboratory studies of disinfection.  
 




is the use of surrogate viruses. A wide range of surrogate viruses for HuNoV 
have been investigated, including non-human mammalian viruses and 
bacteriophages (33,34). The male-specific coliphage MS2 is one of the more 
commonly used HuNoV surrogates due to low cost, high replication in lab 
settings, absence of animal pathogenicity, similarity in size and genome to 
HuNoV, and ease of quantification in an E. coli plaque assay (35). MS2 has 
served as a valuable tool for laboratory studies of HuNoV fomite recovery and 
disinfection (36-39). However, no surrogate is perfect, and MS2 is unlikely to 
accurately model HuNoV disinfection (40-43). Additionally, surrogates cannot fill 
the gap in knowledge around prevalence of infectious HuNoV that is required for 
robust risk assessments.  
 
The newly developed human intestinal enteroid (HIE) model for cultivation of 
HuNoV offers promise in filling the gaps left by molecular detection and surrogate 
studies (10). The HIE approach, introduced in 2016, represents the first 
successful attempt to culture HuNoV (10). Multiple researchers have 
demonstrated the reproducibility of HuNoV replication in monolayers seeded 
from stem-cell derived HIEs (44-46,10,47). The HIE method relies on measuring 
fold increase in viral RNA between 1 and 72 hours post infection which precludes 
absolute quantification of viral particles (48). Due to the nature of HIE cells, no 
direct quantification, like that achieved with plaque assay, can occur (10). 




with consistent inputs (46). Additionally, the HIE cell model is resource and time 
intense, requiring multiple weeks of growth in order to process a single sample 
(48). Despite these challenges, HIEs remain the only way to cultivate HuNoV and 
offer the opportunity to address gaps in our understanding of HuNoV prevalence, 
risk modeling, and susceptibility to disinfectants.  
 
Use of the HIE model to cultivate swab recovered HuNoV is necessary to 
measure population exposures, target areas for intervention, enhance risk 
assessment data, and conduct disinfection studies. However, the HIE method 
has not been applied to cultivation of swab-recovered HuNoVs. We investigated 
how the complex swab matrix, which often includes salts and surfactants, 
impacts HuNoV replication in HIE cells. Additionally, we determined if the 
process of swabbing and recovery will yield in-tact HuNoV that is capable of 
replication in HIE cells. 
 
2 Methods 
2.1 Viral Stock Preparation 
HuNoV stool suspensions were prepared from a community pediatric HuNoV 
case that was graciously provided by Dr. Natalie Exum. Stool was lab confirmed 




capsid region (49). Raw stool was diluted to 10% in phosphate buffered saline 
(PBS) and filtered through a 0.45µm filter. Samples were portioned and stored at 
-80°C from collection until time of testing. MS2 stocks were propagated and 
purified with ultra-membrane filtration before portioning and storage at -80°C, as 
previously described (35,41).  
 
2.2 Fomite Preparation and Inoculation 
Three items representing common high touch fomites found in community 
settings were tested for HuNoV recovery in this study - a hospital bed tray 
(melamine-laminate), a lever-style door handle (brushed stainless steel), and a 
hand sanitizer dispenser (acrylonitrile butadiene styrene (ABS) plastic). All items 
were kindly provided by Johns Hopkins Hospital Facilities Management. Each 
item was marked with multiple 3 cm2 areas for sampling; swab areas were on the 
top surface of the bed tray, the smooth grab surface of the door handle, and the 
front of the push lever of the sanitizer dispenser (Figure 1). Prior to inoculation, 
fomites were disinfected with sequential applications of 10% bleach, 70% 
ethanol, and distilled water. Each fomite was then exposed to a UV lamp 
(253.5nm) for 30 minutes. 
 
Fomite inoculum consisted of a 10% dilution of HuNoV stool suspension in PBS. 




stated otherwise, 50μL of inoculum was applied to the fomite per swabbing 
experiment. After inoculation, each fomite was immediately swabbed horizontally, 
vertically, and then diagonally (Figure 2). 
 
2.3 Swabbing Method 
Individually wrapped, sterile 100% polyurethane foam (PUF) swabs (STX708A, 
Texwipe, Kernersville, NC, USA), common in industry fomite monitoring (29), 
were used to recover HuNoV from inoculated fomites. Prior to swabbing, each 
swab was placed in a 15mL conical tube that contained 2mL PBS plus 0.02% 
Tween80 detergent (Millipore Sigma, Burlington, MA, USA). Tween80 was added 
to swabbing medium as it has been shown to increase recovery of 
microorganisms from fomites (28). Swab medium was weighed before and after 
swabbing to measure volume loss and calculate final eluate volume. To recover 
viruses, swab-containing tubes were vortexed for 30s, centrifuged for 1 min, and 
then liquid was manually recovered from foam swab heads by pressing the swab 
stick along the side of the tube until no further liquid could be squeezed out. After 
elution, recovered swab medium was stored at -80C until testing.  
 
2.4 RNA Extraction and Detection via RT-qPCR 




USA) and the Direct-Zol RNA purification kit (Zymo Research, Irvine, CA, USA) 
as described previously (10). RNA was detected and quantified using the 
QuantiTect Probe RT-PCR Kit (Qiagen, Hilden, Germany). Primers and probes 
specific to the MS2 replicase gene (35) or the HuNoV ORF1-ORF2 junction (50) 
were used in the RT-qPCR assay. MS2 was quantified from molecular assays 
with an RNA dilution series with known amounts of coliphage. HuNoV RNA was 
converted from a cycle threshold value (Ct) to genome equivalents (GE) using in 
vitro RNA transcripts kindly provided by Michael Kulka (FDA, Silver Spring, MD, 
USA). Transcripts were derived from plasmid pNoV/MD145 which contained a 
full-length synthetic cDNA copy of a HuNoV GII strain (51). Molecular percent 
recovery was calculated by comparing HuNoV GE applied to surface to HuNoV 
GE in total recovered swab eluate. We confirmed the absence of RT-qPCR 
inhibition for HuNoV and MS2 assays with a spiked internal positive control (data 
not shown).  
 
2.5 Infectivity Methods 
The HIE method for culturing HuNoV has been described in detail previously 
(46,10). Briefly, a secretor-positive jejunal HIE cell line (J2), kindly provided by 
Mary Estes (Baylor College of Medicine, Houston, TX), was maintained as 
undifferentiated three-dimensional (3D) (i.e., spheroid) cultures embedded in 




and Human IntestiCult media (STEMCELL Technologies, Vancouver, Canada). 
After 7 days of growth, 3D cultures were either passaged 1:2, archived in LiN2, 
or used to seed monolayers. Passaged HIE monolayers were grown for two days 
in IntestiCult supplemented with 10 µM Y-27632 (ROCK Inhibitor), 10 µM 
CHIR99021 (GSK3 inhibitor) (STEMCELL Technologies, Vancouver, Canada) 
and 1000μm / mL Primocin antimicrobial agent (InvivoGen, San Diego, CA, 
USA). After two days CHIR99021 was removed from the growth media. 
 
To seed monolayers, HIEs were dissociated to a single cell suspension with 
Trypsin and plated 1:2 as undifferentiated monolayers in Matrigel-coated 96-well 
cell culture plates. Monolayers were grown for two days with IntestiCult 
supplemented with 10 µM Y-27632 and then differentiated for 5 days prior to 
infection with media lacking Wnt3a, R-spondin-1, and SB202190 (p38 MAPK 
inhibitor), as previously described (52,53). 
 
Confluent, differentiated HIE monolayers were infected apically in duplicate and 
all infection media was supplemented with 500 µM of glycochenodeoxycholic 
acid (GCDCA; Sigma-Aldrich, St. Louis, MO, USA). After 1 hour of incubation at 
37°C in 5% CO2, supernatant was removed and monolayers were washed three 
times with complete media without growth factors. For each set of infections, one 




in 5% CO2 for 72 hours post infection (hpi). Following the 72-hour incubation, the 
supernatant and monolayer cells were frozen at -80°C. We then extracted RNA 
from 1 hpi and 72 hpi monolayer cells and supernatants.  
 
A standard 10-fold dilution, double agar plaque assay was used to enumerate 
infectious MS2 coliphage as plaque forming units (PFU) following the protocol 
described by Bae and Schwab (35). 
 
2.6 Statistical Methods 
Statistical analyses were performed in Stata 13 and R 3.6.1 (54,55). HuNoV 
replication was measured as the fold increase between HuNoV RNA copies 
measured at 1 and 72 hpi; samples were considered negative for replication if 
the fold increase was less than five. Values below the RT-qPCR LOD (44.3 RNA 
copies/ 5uL) were replaced with the LOD value. 
 
3 Results 
Fifty individual swabbing experiments were performed: 29 on a hospital bed tray, 
10 on a lever-style door handle, and 11 on a hand sanitizer dispenser. Of these 
50 experiments, 30 were positive for infectious HuNoV as measured by a 5-fold 




on 14 runs of seven dilutions in duplicate, the RT-qPCR limit of detection (LOD) 
was determined to be 44.3 viral RNA copies/ 5uL, as calculated using the 
discrete threshold method (56).  
 
Bed tray experiments were used to identify the volume and range of HuNoV 
inoculum required for successful replication. Ten swabs were recovered from the 
bed tray after inoculation with 100μL of HuNoV stool suspension ranging in 
concentration from 2.8 x 105 to 2.8 x 106 HuNoV GE/ cm2 (Figure 3). Three (30%) 
of the 100μL inoculum fomite-recovered swabs were positive for infectious 
HuNoV. Additionally, 50μL inoculum was used in 19 bed tray swab experiments 
with HuNoV concentrations from 3.5 x 104 to 8.7 x 106 HuNoV GE/ cm2 (Figure 
3). Eleven (58%) of the 50μL inoculum fomite-recovered swabs were positive for 
infectious HuNoV. The lowest fomite inoculum that resulted in recovery and 
detection of infectious HuNoV was 1.4 x 105 GE/ cm2. Less than 50% of swabs 
from fomites inoculated in the 105 HuNoV GE/ cm2 contained measurable 
infectious HuNoV, even with similar amounts of viral input (Figure 3). Viral 
inoculum of 106 HuNoV GE/cm2 or greater resulted in 0% recovery when 100μL 
fomite inoculum was used and 100% recovery when 50μL inoculum was used.  
 
Once it was established that 50μL HuNoV stool suspension with at least 1.4 x 




we measured recovery from metal door handles and plastic sanitizer dispensers 
inoculated with 106 or greater HuNoV GE/ cm2. The percent of swabs that were 
positive for infectious HuNoV from bed tray, door handle, and sanitizer dispenser 
experiments were 100% (n = 7), 80% (n = 10), and 73% (n =11), respectively. 
Door handle-recovered swabs had the highest HuNoV replication, as measured 
by fold increase in HuNoV GE between 1 and 72 hpi in HIEs. The average fold 
increase in HuNoV GE was 2.3 x 103 (SD 3.1x103, n = 10) for door handle 
experiments, 1.1 x 103 (SD 1.3 x 103, n = 11) for sanitizer dispenser experiments, 
and 2.7 x 102 (SD 3.3 x 102, n = 7) for bed tray experiments (Figure 4). Recovery 
of infectious HuNoV was not significantly different across the three fomites when 
considering percent of positive swabs (ANOVA p-value = 0.5) or when 
considering measured fold increase (ANOVA p-value = 0.2). 
 
Swabs recovered from fomites infected with 50μL of HuNoV stool suspension 
were tested for molecular HuNoV recovery, in addition to HuNoV replication. 
Average percent recovery of HuNoV measured by molecular methods was 
0.74% (range 0.03% to 4.3%) and was not significantly different across the three 
tested fomite types (ANOVA p-value = 0.3) (Figure 5). Twelve of 40 swabs had 
molecular HuNoV recovery below 0.1% and 8 of these swabs were positive for 
infectious HuNoV. Percent of swabs positive for infectious HuNoV in the two 
higher categories of molecular recovery - 0.1 to 1% and above 1% - were 77% (7 




HuNoV by molecular methods; five of these were also negative for infectious 
HuNoV. When controlling for HuNoV GE on fomite and fomite type, no 
relationship was found between detection of infectious HuNoV and molecular 
HuNoV percent recovery (binomial regression, all p-values > 0.04). 
 
In addition to HuNoV stool filtrate, fomite inoculum for 25 swabbing experiments 
contained MS2 ranging from 1.86 x 102 – 3 x 106 GE/ cm2. Infectious MS2 
measured by plaque assay was found in all swab experiments run with MS2, and 
MS2 RNA was also detected in 18 of these swabs (Figure 6). Two bed tray-
recovered swabs negative for MS2 RNA but not infectious MS2 were from 
fomites inoculated with < 2 x 103 MS2 GE/ cm2. The other 7 swabs negative for 
MS2 RNA and positive for infectious MS2 were from door handle or sanitizer 
dispenser experiments with 3.1 x 104 MS2 GE/ cm2 in fomite inoculum. Average 
percent recovery of MS2 RNA was 74%  by RT-qPCR and average percent 
recovery of infectious MS2 was 75% by plaque assay; no difference in either 
measure was found across fomites types (ANOVA p-values = 0.9 and 0.4).  
 
4 Discussion 
Fomite transmission of HuNoV plays an important role in initiating and prolonging 
outbreaks. Additionally, the presence of HuNoV on fomites can inform measures 




inactivation methods. Fomite swabbing is necessary to understanding the 
distribution, exposure, and persistence of HuNoV. The pioneering development 
of an HIE model for culturing infectious HuNoV promises to fill in important gaps 
around detection of infectious HuNoV particles after recovery from fomites (10). 
However, the HIE model faces numerous logistical hurdles before it can be 
readily applied in fomite recovery research (48). This work aimed to tackle the 
first of these hurdles - whether swab recovered virus can successfully replicate in 
HIEs. We demonstrated that HuNoV can be experimentally applied to fomites, 
recovered via swab, eluted, and subsequently replicate in HIE cell culture. Swab 
eluate comprised of PBS plus Tween80 does not prevent growth of HIEs or 
replication of HuNoV in HIE culture, paving the way for use of the HIE model to 
cultivate swab-recovered HuNoV. Our base experiments used a hospital bed tray 
with a textured, laminated surface, as this type of fomite is common in health 
care settings where fomite swabbing is particularly necessary (8). We determined 
that at least 1.4 x 105 HuNoV GE/ cm2 must be present on a surface in order to 
successfully recover infectious HuNoV. Accounting for losses from swabbing, this 
value is consistent with previous reports of 103 - 104 GE/ HIE well as a 
requirement for successful HuNoV replication (46,10). We also found that high 
viral titer applied to the surface in larger volumes (100μL) did not result in 
successful recovery of infectious HuNoV. This may be due to dilution introduced 
by larger volumes and the inability of the pre-moistened swab to fully recover 




and thus small droplets inoculated onto fomites can be clinically relevant (57). 
 
We first measured presence of infectious HuNoV as binary, where a swab was 
considered positive if we observed a 5-fold or greater increase in GE between 1 
and 72 hpi in HIEs. The number of swabs positive for infectious HuNoV was 
inconsistent even within equivalent surface inoculum categories, except for high 
viral titer (>106) in 50μL of inoculum. This indicates that high concentration viral 
titers provide the most successful and consistent recovery of positive virus, 
consistent with previous work on molecular recovery of HuNoV (58). These 
values can guide future bench-scale evaluations of HuNoV fomite inactivation 
and having the HIE system used as a binary measure of infectious HuNoV post-
fomite disinfection will be a powerful first step when developing risk models. 
Quantification may be possible by inoculating portions of samples in a dilution 
series into the HIE system, with subsequent enumeration of viral load using the 
most probable number (MPN) method.  Another potential option for quantifying 
recovered infectious HuNoV is the fold increase in GE between 1 and 72 hpi in 
HIEs. Consistent with previous work, we found that fold increases ranged from 
10 - 10,000 and varied from 2 - 3 logs within tests that used equivalent surface 
inoculum (45,46,59). We are not the first to report high variability among 
measured fold increase in HIEs and this inconsistency remains a key challenge 





In addition to the melamine-laminate bed tray, we tested two other fomites 
common in healthcare settings - a brushed stainless steel lever-type door handle 
and a smooth ABS plastic sanitizer dispenser. . We found no measurable 
differences in recovery of infectious HuNoV off of these two fomites, compared to 
bed tray experiments. This is promising for future environmental monitoring work 
as the data suggest that multiple types of fomites can be swabbed for infectious 
HuNoV.  
 
We measured molecular recovery of HuNoV with RT-qPCR to serve as a point of 
comparison with infectious HuNoV data. We found that average recovery of 
HuNoV from fomites as measured by molecular methods was 0.74% and ranged 
from 0.03% to 4.3%. These recovery values are slightly lower than most reported 
in the literature, which range from 4.3% - 100% (26,60,27,61,62,58). However, it 
is important to note that previously reported recovery of HuNoV from hard 
surfaces is highly variable both within and across studies and when reported 
errors are accounted for, our observations fall within previously reported ranges 
(29,9,62,25). Of note, even when molecular recovery of HuNoV was below 0.1%, 
approximately half of swabs were positive for infectious HuNoV. It appears that 
even in scenarios with low molecular recovery, infectious HuNoV particles can 




HuNoV as measured by RT-qPCR, but were positive for infectious virus. This 
discrepancy between infectivity and molecular measures has been observed in 
other viruses and is likely due to methodological limitations of the RT-qPCR 
assay (63,64). Additionally, a smaller amount of sample (5µL) was tested in RT-
qPCR runs, as compared to 250µL for HIE infection, which may reduce the 
efficacy of RT-qPCR for low-titer samples. 
 
As is common in HuNoV literature, we also tested the surrogate virus MS2 
coliphage in a subset of swabbing experiments with both molecular and infectivity 
methods (65,66). Recovery of MS2 via molecular (74%) and infectivity (75%) 
methods were comparable, which provides validity to our experimental set-up. 
However, MS2 recovery was 2 logs greater than molecular HuNoV recovery 
(0.74%). This recovery variation between viruses, particularly those used as 
surrogates, has been described in detail in the literature (67,62). Differences in 
virus structure can affect viral adhesion to fomites, containers, and swabs, which 
can then impact recovery (68). Our work adds to the extensive literature that 
questions the accuracy of MS2 coliphage as a HuNoV surrogate (35,41,69,70). 
Though MS2 retains value due to its ease of cultivation, the data from this study 
shows that it cannot be employed as a replacement for measuring HuNoV 
recovery from fomites. Thus, even when faced with multiple methodological 
hurdles, the HIE system has significant value as it remains the only option for 





This work is subject to limitations that were beyond the scope of the current 
project. First, we evaluated the behavior of a single HuNoV strain - GII.4 Sydney 
- as previous work on HIEs indicates that this strain replicates most successfully 
(46). The variation in replication of different HuNoV strains is a well-documented 
limitation of the current HIE method (46,48,10). Low sample sizes due to 
methodological limitations of the HIE method should also be considered when 
generalizing specific recovery measurements from this work. We also focused on 
a single swabbing protocol and though the literature indicates good success with 
foam swabs pre-moistened in PBS plus Tween80, we could be missing recovery 
variability found by other methods (61). Additionally, we did not examine drying 
as we were focused on confirming fomite recovery of infectious HuNoV and 
previous literature indicates a significant reduction in recovery after drying (61). 
Finally, we did not address the role that viral aggregation may play in observed 
recovery efficiencies (68).  
 
We have successfully demonstrated that the HIE culture method can be used to 
cultivate infectious HuNoV recovered from fomites under prescribed conditions. 
This adds new utility to the HIE method and opens the door for numerous studies 
aimed at cultivating fomite recovered virus. Though the HIE method remains an 




monitoring and disinfection studies. The most important next steps will be to 
address some of the hurdles that prevent wide application of the HIE system in 
monitoring. It will be important that future work examines factors that impact 
inconsistent replication of HuNoV in HIEs and aims to develop reliable methods 
of quantification. Additionally, reduction of the time, labor, and expense required 
to use HIEs for HuNoV cultivation will significantly increase the applicability of the 
method. The HIE method remains the only widely reproducibly way to verify 
infectious HuNoV and our ability to recover and cultivate swab-recovered viruses 
moves the field one step closer to a broadly applicable system that can measure 
infectious HuNoV in the environment.  
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Figure 3.1 Surfaces tested for human norovirus swab recovery.  
 
Red boxes indicate 3cm3 areas that were inoculated and swabbed. 
  
Hospital Bed Tray Lever Style Door Handle Hand Sanitizer Dispenser 





Figure 3.2 Direction and order of swabbing on surfaces tested for human 
norovirus swab recovery.  
 





Figure 3.3 Number of fomite-recovered swabs that were tested and positive for 
infectious HuNoV (HuNoV) by surface inoculum volume and amount of HuNoV 
on fomite (genome equivalents(GE)/ cm2).  
 
Non-porous laminated fiberboard from a hospital bed tray was inoculated with 
either 50 or 100μL HuNoV stool suspension containing 104, 105, or 106 HuNoV 
GE/ cm2. Fomites were swabbed with macrofoam swabs pre-moistened in 
phosphate buffered saline plus 0.02% Tween80. Human intestinal enteroid (HIE) 
monolayers were infected with swab eluate and were considered positive for 
infectious HuNoV if the fold increase in HuNoV GE between 1 and 72 hours post 




Figure 3.4 HuNoV (HuNoV) replication from swabs recovered off lab-inoculated 
fomites.  
 
Three fomites - a laminated fiberboard hospital bed tray (n = 7), a brushed 
stainless steel door handle (n =8), and an acrylonitrile butadiene styrene (ABS) 
plastic sanitizer dispenser (n = 7) - were  inoculated with 50μL HuNoV stool 
suspension containing 106 or greater HuNoV genome equivalents (GE) per cm2. 
Fomites were swabbed with macrofoam swabs pre-moistened in phosphate 
buffered saline plus 0.02% Tween80. Human intestinal enteroid (HIE) 
monolayers were infected with swab eluate and HuNoV replication is reported as 
the fold increase in HuNoV GE between 1 and 72 hours post infection (hpi). Fold-
increase of five or lower was considered negative for infectious HuNoV; only 





Figure 3.5 Number of swabs tested and with detectable infectious HuNoV 
(HuNoV) compared to molecular percent recovery of HuNoV from experimentally 
inoculated fomites.  
 
One of three fomites - hospital bed tray (n = 19), door handle (n = 10), or 
sanitizer dispenser (n = 11) - were inoculated with 50μL of HuNoV stool 
suspension containing 104 or greater HuNoV genome equivalents (GE) per cm2. 
Fomites were swabbed with macrofoam swabs pre-moistened in phosphate 
buffered saline plus 0.02% Tween80. Human intestinal enteroid (HIE) 
monolayers were infected with swab eluate and were considered positive for 
infectious HuNoV if the fold increase in HuNoV GE between 1 and 72 hours post 
infection (hpi) was greater than five. Molecular percent recovery of HuNoV was 
calculated by comparing HuNoV GE added to fomite to HuNoV GE in recovered 





Figure 3.6 Recovery of MS2 by infectivity and molecular methods for each 
individual swab experiment.  
 
MS2 recovery is equivalent to plaque forming units for infectivity and genome 
equivalents (GE) for molecular. Fomites were inoculated with 50μL HuNoV stool 
suspension mixed with 102 - 107 MS2 GE/ cm2. Fomites were swabbed with 
macrofoam swabs pre-moistened in phosphate buffered saline plus 0.02% 
Tween80. Swab eluate was tested for MS2 replication with an E. coli plaque 
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Quantitative microbial risk assessment of human 
norovirus infection in environmental service workers 
due to healthcare-associated fomites 
Katie Overbey, Ghassan Hamra, Keeve Nachman, Clare Rock, Kellogg Schwab 
 
Abstract 
Objective: To quantify human norovirus (HuNoV) infection risk in healthcare 
environmental service workers (ESWs) from a single fomite contact in areas 
occupied by HuNoV positive patients. An additional aim was to further quantify 
the risk of secondary HuNoV transmission and illness in healthcare settings as a 
result of fomite transfer from ESWs. 
Design: A quantitative microbial risk assessment employing 2D Monte Carlo to 
model variability and uncertainty of parameters to estimate HuNoV infection in 
multiple fomite contact scenarios. Scenarios were defined by: source of HuNoV 
(vomit or diarrhea), location (bathroom or patient room), and target outcome 
(ESW illness or secondary illness).  




Results: The risk of an ESW becoming ill with HuNoV was as high as 1:3 for 
single fomite contact in a room where a patient experienced diarrhea. Risk 
estimates for vomit scenarios were four orders of magnitude lower than those for 
diarrhea scenarios. Risk of secondary illness from touching a common surface 
was 32% lower than risk of ESW illness in diarrhea scenarios and 80% lower in 
vomit scenarios.  
Conclusions: A single fomite contact can lead to sizable HuNoV infection risk in 
ESWs, who can also transfer virus to secondary surfaces, initiating further 
infections. ESWs likely face occupational health risks from fomite-mediated 
infections and robust interventions are needed. 
 
1 Introduction 
Human noroviruses (HuNoVs) cause approximately 685 million illnesses every 
year and cost the global economy $64.5 billion annually (1-3). In many countries, 
including the United States, the majority of HuNoV outbreaks occur in healthcare 
facilities, including hospitals and long-term care facilities (4,5).  The burden of 
healthcare-associated norovirus infections is high, and the presence of 
immunocompromised and elderly patients can prolong outbreaks in these 
settings, exposing health care providers for months at a time (6-12). In many 
healthcare-associated outbreaks, staff make up the majority of cases (8,9). 




and reduction in hospital capacity due to closures and ill staff (13,14). For 
example, a single HuNoV outbreak in a tertiary care hospital in 2004 led to 265 
healthcare worker illnesses and an estimated cost of $657,644 (9). 
 
HuNoVs possess multiple characteristics that make them a significant pathogen 
in healthcare settings. HuNoVs are shed in high titer from the vomit and stool of 
symptomatic individuals (15,16). Of particular challenge, there is frequent 
asymptomatic shedding of infectious virus (17), and the infectious dose of 
HuNoVs is very low, estimated to be between 10-100 particles (18). In a 
healthcare setting, the presence of immunocompromised patients can increase 
the likelihood of HuNoV spread as these patients can chronically shed high titers 
of HuNoV (4,19).  
 
While multiple studies have aimed to quantify the impact of HuNoVs of 
healthcare staff, a vast majority of these studies have focused on nurses, 
doctors, and other clinical staff (8,20,11,14). In many labor sectors, including 
healthcare, cleaning and facilities staff are frequently understudied (21,22). In the 
healthcare setting, environmental service workers (ESWs) clean and disinfect 
facilities and are responsible for executing infection control protocols. ESWs are 
often in patient areas with a similar frequency as some clinical staff, but very little 




COVID-19 among cleaning staff in a clinic to be higher than that of clinical staff, 
which points to a potential undetected disease burden in ESWs (21). The US 
Department of Labor reports that janitors and cleaning staff have a higher 
incidence of illness and injury than registered nurses (23).  
 
Significant resources have been dedicated to assessing knowledge, providing 
education, and changing behaviors among ESWs to improve cleaning and 
disinfection practices (24-27). There is evidence that integrating ESWs into the 
planning of infection control procedures results in reduced nosocomial infections 
among patients (11,28). However, current research fails to examine the health 
burden placed on ESWs who work in close contact with ill individuals and 
contaminated environments.  
  
The majority of healthcare-associated HuNoV outbreaks begin due to 
environmental contamination, and fomites represent a significant environmental 
route of exposure (29,30,11,31-33).  Despite the concerns with fomite 
transmission of HuNoVs, there is evidence that healthcare workers lack 
knowledge about fomites as a pathogen vector and may not follow appropriate 
hand hygiene practices after fomite contact (34,35). When focusing on ESWs, 
the role of fomite transmission of HuNoVs becomes even more important as 




likely to underestimate the risks posed to them from fomites and may be less 
likely to follow hand hygiene practices after contacting fomites (24). 
 
To quantify the risks faced by ESWs during HuNoV outbreaks, a quantitative 
microbial risk assessment (QMRA) is necessary. QMRA is a technique to model 
infection and illness risk in a population exposed to microorganisms, based on a 
four-step process: hazard identification, exposure assessment, dose-response, 
and risk characterization (37). It allows for the quantification of infection risks 
under multiple scenarios, which can be useful in estimating health burdens, 
designing intervention strategies, and identifying research needs. Each step 
requires detailed analysis of a scenario of interest and requires quantitative 
information to develop a final model. In QMRA, it is possible to integrate both 
variability, which describes inherent differences in the population of interest, and 
uncertainty, which reflects imperfect knowledge (38). In general, uncertainty can 
be reduced with additional data and improved models, while variability will not 
change with more measurements, though it may be better characterized (38). 
Analysis of both variability and uncertainty in a QMRA can be achieved through 
the use of two-dimensional Monte-Carlo (2D MC) (39). 
 
The goal of this work was to use a 2D MC method to quantify HuNoV infection 




HuNoV positive patients who are actively shedding HuNoV. This work is one of 
the first to develop a QMRA for HuNoV transmission from fomites in healthcare 
facilities. Our model considered illness in ESWs as an endpoint, in addition to 
secondary illness as a result of fomite transfer from ESWs. 
 
2 Methods 
2.1 Model Scenarios 
Eight scenarios were developed to compare HuNoV infection risk from different 
HuNoV sources, locations, and populations experiencing the health outcome 
(Table 1). For each scenario we aimed to develop a QMRA and 2D MC model 
that was protective of public health by modeling high exposure values that were 
plausible based on current literature. We quantified the risk of HuNoV infection 
from a single fomite contact that occurred after a single HuNoV source event – 
either vomit or diarrhea from an infected patient (Figure 1). We modeled multiple 
scenarios to examine risk differences between the type of source event and the 
location of the source event, either in the patient’s bathroom or in their main 
room. Additionally, we were interested in two populations for the final health 
outcome of HuNoV infections – (1) ESWs who directly touch contaminated 
fomites and (2) other healthcare workers who touch a shared surface that was 




(“secondary fomite infections”). In all scenarios, the initial fomite contact is made 
by an ESW.  
 
In Table 1, scenario number indicates the source event and location, while 
scenario letter refers to the population of interest for HuNoV infection. Scenario 1 
modeled a patient vomiting in the bathroom, scenario 2 modeled a patient having 
diarrhea in the bathroom, scenario 3 modeled a patient vomiting in their room, 
and scenario 4 modeled a patient having diarrhea in their room. For each 
numerical scenario, there is an “a” and “b” scenario reflecting target health 
outcome – either ESWs develop a HuNoV infection (outcome a) or the 
contamination of shared ward fomites leads to infection in persons who contact 
those fomites (outcome b, “secondary fomite infections”). For in-bathroom 
scenarios, both source events were assumed to occur in the toilet, while for in-
room events we assumed the use of a bed pan for diarrhea and a basin for 
vomiting. The touch fomite of interest in bathroom scenarios was the bathroom 
door handle and for in-patient room scenarios the fomite of interest was the 
patient bed rail. For secondary fomite infections, the contact surface was 
modeled as a door handle in common space on the ward. Model assumptions 





2.2 Modeling Approach 
A 2D MC approach was used to model variability and uncertainty of inputs. The 
R package “mc2d” was used to build and evaluate all models (39). Distributions 
for inputs were designated as variability (inherent population differences), 
uncertainty (result of imperfect knowledge), or a combination of both. In some 
instances, fixed values were used for inputs. For inputs that were defined only by 
variability, distributions were randomly sampled to provide final estimates. For 
inputs defined by both uncertainty and variability, we first sampled uncertain 
parameters. Then, any uncertain parameters were carried into a variability 
distribution and randomly sampled. The final model resulted in risk estimates that 
reflect variability across the population, conditional upon uncertainty parameters. 
Model iterations were set at 1000 for the variability dimension and 100 for 
uncertainty. Stability of measurements was tested by running 10 different seed 
values. For each scenario, different seed values resulted in overlapping standard 
deviation intervals for each median risk estimate (data not shown).  
 
2.3 Model Parameters 
All parameters, distributions, and sources used in our models are shown in Table 
3. The corresponding variable notation listed in Table 3 is provided 
parenthetically in text and corresponds to variable names in the R code provided 




corresponding R code. In general, uncertainty distributions were truncated at 
minimum and maximum values of corresponding variability distributions, and 
variability distributions were truncated at biologically impossible values (ex. stool 
production below zero, transfer proportions greater than 1). 
 
2.4 Norovirus Shedding  
The mean concentration of HuNoV in vomit (m.vv) was modeled as an 
uncertainty distribution using data from human challenge studies. We focused on 
one study that infected patients with GII.2 snow mountain virus and measured a 
mean shedding of 1.6 x 105 HuNoV genome equivalents (GE)/ mL vomitus with a 
standard deviation of 4.5 x 104 GE/ mL (40). This study was selected because it 
used a genotype II HuNoV, which is widely circulated in healthcare facilities 
(5,31). The mean virus concentration in vomit was modeled using a normal 
distribution. Based on a previously conducted QMRA, we then chose to model 
variability in norovirus concentration in vomit (c.vv) using a BetaPert distribution 
with a mode selected from the uncertainty distribution, a minimum of 2,200 GE/ 
mL, and a maximum of 1.2 x 107 GE/ mL (41,42).  
 
The next parameter modeled was the volume of vomit produced in a single 
event. We define a vomit event as the production of vomitus that occurs within a 




disease course and not later when dry-heave or retching events may be more 
likely. Previous literature indicates that vomitus greater than 800 mL is 
considered abnormally high for norovirus patients and less than 50 mL is 
considered a “dry-heave” event (43). In HuNoV challenge studies, mean 
production of vomit during an entire course of infection with HuNoV GII.2 snow 
mountain resulted in an average of 845 mL of vomitus with a standard deviation 
of 227 mL and patients experienced an average of 2 vomit events through the 
course of their infection (40). To model uncertainty of the mean volume of vomit 
(m.vlv) from a single event, total volume of vomit was modeled with a normal 
distribution with mean 845 mL and standard deviation of 227 mL, then this value 
was divide by two to obtain estimated mean volume of vomit for one event. The 
resulting estimated mean was used as the mode for a BetaPert distribution with a 
minimum of 50 mL and maximum of 800 mL to model variability (vl.v). 
 
Mean mass of feces in one diarrhea event (m.mf) was estimated using mean 
diarrhea amounts from Read et al. (44) to obtain an average daily mass of 437 g 
with standard deviation of 76 g. These values were divided by the estimated 
average number of daily bowel movements for a norovirus patient (4.45) (45). 
This resulted in a normal distribution with mean of 98.2 g and standard deviation 
of 17.08 g. The final mass of feces (m.f) was modeled using a BetaPert 
distribution with a range of 14.6 to 449.4 g which represent minimum and 




Concentration of norovirus in feces (c.vf) was modeled as a variability parameter 
with a BetaPert distribution using values from a previous QMRA (42). 
 
2.5 Aerosolization and Fomite Deposition 
For the amount of virus released into room air, two parameters were modeled: 
the proportion of virus aerosolized during vomiting and the proportion aerosolized 
during flushing a toilet. These two values were assumed to be additive and 
degradation of virus in vomitus was not considered. Additionally, we assumed 
that diarrhea events only produced aerosol from flushing and not during 
defecation as individuals will block air movement while seated. 
 
Particles released from vomit and flush events were considered to reach their 
maximum number in one m3 space around the toilet as research has indicated an 
initial dispersion of particles post-flush of approximately 1 m above the ground 
(46). Particles were subsequently assumed to evenly disperse through the room 
within 1 minute (47). The total amount of virus per m3 was calculated by dividing 
total particles aerosolized by room volume (46). 
 
To calculate the norovirus aerosolization from a vomit event (p.av) we used data 




simulated vomiting event with low viscosity vomitus, as these values reflect a 
worst case scenario. Variability in the proportion of particles aerosolized from one 
vomit event was modeled as a normal distribution based on concentration of 
virus in vomit – for low titer vomitus (<1010 GE) we used a mean of 2.8 x 10-5 and 
a standard deviation of 1 x 10-5, while for high titer vomitus (≥1010 GE) we used a 
mean of 1.3 x 10-4 and a standard deviation of 1 x 10-4. We tested cutoff values 
from 107 to 1010 for low versus high titer vomitus and no difference was observed 
in final risk estimates (data not shown). 
 
For variability in aerosolization of norovirus from toilet flushing (p.af) we used 
data from Barker and Jones (48) where a toilet bowl was inoculated with a known 
amount of the HuNoV surrogate MS2, flushed, and air concentration was 
measured. For one flush, 2.42 x 10-7 of in-toilet virus was aerosolized and this 
was modeled as the mean of a normal distribution with a standard deviation of 
6.91 x 10-8.  
 
Bathroom volume was calculated from a study that measured areas of 
bathrooms in a modern tertiary care hospital (49). The height of the room was 
assumed to be 2.39 m, which meets Facility Guidelines Institute (FGI) guidelines 
for hospital construction (50). Area values were multiplied by 2.39 and values 




room volumes, suggested room areas from the literature were multiplied by an 
assumed room height of 2.39 m and averaged, resulting in an estimated patient 
room volume of 26.5 m3 (51). It was assumed that patient room doors and 
bathroom doors were closed during source events and that air mixing between 
the rooms did not occur. We then calculated the concentration of HuNoV per m3 
in the room air for each scenario using amount of virus aerosolized from vomit 
event and/ or toilet flush.  
 
Equations for each scenario were: 
Vomit in Bathroom, Immediately Post Flush (s1a, s1b) 
(c.vv * vl.v * (p.av + p.af)) / vlr   [c.va1] 
Diarrhea in Bathroom, Immediately Post Flush (s2a, s2b) 
(c.vf * m.f * p.af ) / vlr    [c.va2] 
Vomit in Patient Room, Immediately After Event (s3a, s3b) 
(c.vv * vl.v * p.av) / vlr   [c.va3] 
For scenarios 4a and 4b (diarrhea in patient room) we assumed no 
aerosolization due to the absence of both vomiting and toilet flushing.  
 
To model the settling rate of aerosolized virus on to fomites, we used air 




inoculated with MS2, the authors measured a 93% reduction in virus particles in 
air after 30 minutes post-flush. We estimated that 93% of virus in a m3 area will 
fall out on a m2 in 30 minutes, which results in a fomite deposition rate of 0.031 
from m3 to m2 per minute, for up to 30 minutes. After 30 minutes, we assumed 
that 100% of aerosolized particles deposited on to fomites. We modeled time 
since event (delt.t) as a uniform distribution from 1 to 1440 minutes, assuming an 
ESW would enter a room once per day for cleaning (52). 
 
Surface area of hand contact (ah) was estimated by painting a standard metal 
lever-type door handle, having author KO grab the handle to simulate opening a 
door, and measuring the surface area of paint transferred to a sheet of paper. 
This value was 0.001268 m2 and was compared to data on average human hand 
size from the EPA Exposure Factors Handbook to verify that our value was 
plausible (53). We assumed that hand-fomite contact area was constant for both 
fomites used in our scenarios - door handles and bed rails.  
 
To obtain estimates of finger pad area (af) we used a study by Dandekar et al. 
that found the average width of an adult index finger to range from 16 - 20 mm 
and we assumed a square finger pad area for a resulting uniform distribution that 
ranged from 0.000256m2 to 0.0004m2 (54). To calculate virus particles on finger 




between hand touch area and finger pad (r.fh).  
 
2.6 Transfer Efficiencies  
To calculate the proportion of feces transferred to hands during wiping (t.fh), we 
used previous data on mass of feces transfer to hands and our estimate of 98.2 g 
mean stool per event to model this value as a BetaPert distribution with a mode 
of 10-6, minimum of 10-10, and maximum of 10-3 (42). Transfer of HuNoV particles 
from hands to fomites and from fomites to hands were estimated using data from 
Julian et al. (55). We chose reported transfer values for the surrogate virus MS2 
due to its similar size and surface structure compared to HuNoV. We also used 
values reported for recently washed hands under the assumption that in a 
hospital setting recent hand washing is likely to have occurred. This resulted in a 
normal distribution with a mean of 0.15 and a standard deviation of 0.16 for 
transfer of virus from hands to fomites (t.hs) and a normal distribution with a 
mean of 0.26 and a standard deviation of 0.19 for transfer of virus from fomites to 
hands (t.sh). Transfer of virus particles from finger pad to mouth (t.hm) was 
modeled with a normal distribution with a mean of 0.34 and a standard deviation 





2.7 Fomite and Hand Concentrations 
Equations to calculate total amount of HuNoV deposited on touch area were: 
Vomit in Bathroom, Immediately Post Flush (s1a, s1b) 
s.as * c.va * ah     [c.vs1] 
Diarrhea in Bathroom, Immediately Post Flush (s2a, s2b) 
(s.as * c.va * ah) + (m.f * t.fh * c.vf * t.hs) [c.vs2] 
Vomit in Patient Room, Immediately After Event (s3a, s3b) 
s.as * c.va * ah     [c.vs3] 
Diarrhea in Patient Room, Immediately After Event (s4a, s4b) 
m.f * t.fh * c.vf * t.hs        [c.vs4] 
For vomit scenarios (1a, 1b, 3a, 3b) we assumed no hand transfer of virus to 
fomites occurred.  
 
We then used the concentration of virus particles on a fomite to calculate the 
number of virus particles on an ESW’s hands after contact with the fomite: 
c.vs * t.sh  [c.vh] 
 
We also calculated the number of particles an ESW would transfer to secondary 




c.vh * t.hs   [c.v2s] 
 
2.8 Dose 
Norovirus dose was considered the amount of virus particles transferred from a 
finger pad to an ESW’s mouth (“a” scenarios) or secondary contact’s mouth (“b” 
scenarios). We chose to model ingestion as result of finger pad contact because 
previous work has found that 90% of touches to mucous membranes are by 
fingers (60). We assumed that transfer from finger pad to mouth resulted in 
ingestion of 100% of transferred particles. This resulted in the following dose 
equations: 
Norovirus Dose for ESW (1a, 2a, 3a, 4a) 
c.vh * r.hf * t.hm  [D] 
 
Norovirus Dose for Secondary Fomite Contact (1b, 2b, 3b, 4b) 
c.vs2 * t.sh * r.hf * t.hm [D2] 
 
2.9 Dose Response and Endpoint 
The endpoint for this risk model was HuNoV illness in either an ESW or a 




response model to estimate probability of illness, with parameters n and r that 
take the values 2.55 x 10-3 and 0.086, respectively (61,18): 
p(ill/dose) = 1 - (1 + n*dose))^-r    [risk.ill] 
 
2.10 Sensitivity Analysis 
A sensitivity analysis was conducted by calculating the Spearman rank 
correlation coefficient (SRC) for each baseline parameter. SRC values can range 
from -1 to 1 and an |SRC| value closer to 1 indicates higher correlation and 
higher importance of the factor on the final risk value. Baseline parameters were 
defined as values that were supplied to the model as distributions and not 
calculated within the model. Values that were supplied as constants were 
excluded from sensitivity analyses. Baseline parameters evaluated in the final 
sensitivity analysis were concentration of norovirus in vomit (c.vv), volume of 
vomit (vl.v), concentration of norovirus in feces (c.vf), mass of feces (m.f), 
proportion of virus aerosolized from vomit and toilet flush (p.av, p.af), settling rate 
of norovirus from air (s.as), time between source event and fomite contact 
(delt.t), area of finger pad (af), and transfer or norovirus from feces to hands 
(t.fh), from hands to fomites (t.hs), from fomites to hands (t.sh), and from hands 





3 Results  
Median risk estimates and 95% credible intervals for a single fomite contact are 
shown in Table 4. Risk values for diarrhea scenarios (s2, s4) were the same 
when compared across the two locations (bathroom and patient room). Median 
HuNoV infection risk for diarrhea source events was calculated to be 1:3 for 
ESWs whether they were exposed in the bathroom or in the patient room and 1:4 
for secondary contacts. Risk values were lower for vomit scenarios and ranged 
from a 1:23,928 median risk of ESW illness following a vomit event in a patient’s 
bathroom to 1:252,185 median risk for a secondary contact after a vomit event in 
a patient room. Median infection risks from a vomit event were higher in the 
scenarios where the source event occurred in the bathroom (s1), as compared to 
the patient room. Secondary transmission of HuNoV by ESWs resulted in an 
80% decrease in median infection risk for vomit scenarios (s1, s3) and a 32% 
decrease for diarrhea scenarios (s2, s4). 
 
SRC values from the sensitivity analysis for baseline parameters in each 
scenario are shown in Figure 2. Settling rate of norovirus from air to fomites had 
the lowest SRC in all scenarios where it was included. In vomit scenarios (s1, s3) 
the starting concentration of HuNoV in vomit had much less effect on the final 
risk model, compared with the impact of concentration of norovirus in diarrhea 




SRC values compared to aerosolization from toilet flush. In all scenarios with an 
aerosolization component (s1, s2, s3) the time between event and fomite contact 
was strongly correlated to the final risk model (SRC > 0.8). All modeled transfer 
rates had SRC values of 0.8 or higher and in diarrhea scenarios transfer rates 
were significantly correlated with final risk values (SRC 0.99). (add an 
interpretation sentence here) 
 
4 Discussion 
This work is the first to use a QMRA to model infection risk of HuNoV in ESWs 
from fomite contacts in healthcare settings. For a single fomite contact in a room 
where a patient experienced a diarrhea event, the risk of HuNoV infection for 
ESWs was as high as 1:3. Though high, this risk estimate is in line with previous 
reports of HuNoV attack rates in staff between 30% and 90% in hospital 
outbreaks (9,19,14). For scenarios where the ill patient vomited without a 
diarrheal event, the estimated risk to ESWs from fomite contact dropped 
significantly to 1:23,928 for an in-bathroom event and 1:51,504 for an in-room 
event. It is important to emphasize that these risk estimates represent infection 
risk from a single contact event with a single fomite. Data indicates that during 
cleaning, an average of 9 fomites are touched per room visit, with a maximum of 
34 (36). If risks from a single fomite are additive, infection risks from a single 





We found much higher risks of infection from diarrhea source events, compared 
to vomit events. The impact of HuNoV transmission from diarrhea versus vomit 
events remains unclear in the literature. One study reported that vomiting 
patients infect twice the number of people as those who are not vomiting, while 
patients with diarrhea infect 1.4 times the number of people as those without 
diarrhea (62). However, another study indicates that diarrhea is almost 
ubiquitous in index cases for HuNoV outbreaks and that diarrhea had a higher 
association with outbreak development, compared to vomiting (63). One reason 
for the low estimated risks from vomit source events is the focus on just the 
fomite route of transfer and the exclusion of any inhalation of viral particles. 
Previous literature has indicated aerosol transmission of HuNoV and vomiting 
appears to be the main source of HuNoV aerosols (64,65). Aerosolization of 
HuNoV is thought to be highest right after vomiting and presence of HuNoV in 
the air ablates after 3-6 hours post vomit event (64). Our work demonstrates that 
even after reduction of virus aerosolization, fomite exposure to HuNoV can 
remain a significant source of infection. Additionally, risk for fomite exposure may 
actually increase with time since event, which can significantly affect long-term 






For secondary HuNoV infection from contact with a contaminated fomite, risks 
were 32% lower than ESW infection risks in diarrhea scenarios and 80% lower 
than ESW infection risks in vomit scenarios. This aligns with evidence that 
proximity to HuNoV patients increases the likelihood of viral spread in healthcare 
(66). The infection risks faced by secondary fomite contacts are affirmed by 
previous work that shows spread of viral surrogates between multiple rooms and 
fomites in a hospital (67,32).  
 
Our sensitivity analyses indicated that the concentration of HuNoV in vomit was 
much less important in relevant scenarios, when compared to the concentration 
of HuNoV in diarrhea. This is likely due to overall less transmission of HuNoV via 
fomites in vomit scenarios. We also found that a longer time between the source 
event and ESW contact led to a larger risk. This makes sense with the current 
model because we did not model die off and a longer time period would allow 
more virus to settle. However, this finding likely only holds true in scenarios 
where no air inhalation can occur, which is not the case for HuNoV.  
 
We also found that transfer rates were a significant driver of infection risk in our 
models, especially in diarrhea scenarios. This serves to underscore the need for 
more robust and specific data on transfer of HuNoV across different fomites. 




healthcare-associated outbreaks of HuNoV (68,69). 
 
This work was subject to several limitations. Scenarios only accounted for 
HuNoV transfer from patients with active symptoms. Asymptomatic shedding of 
HuNoV is well documented, but literature indicates that symptomatic patients 
remain the main drivers of transmission in healthcare settings (70). We chose not 
to examine the role of hand hygiene or other intervention measures in this model. 
One reason for this was we aimed to capture a worst-case scenario of 
transmission. Further, there is evidence of poor hand hygiene compliance among 
ESWs after fomite contact (36). Evidence also exists that HuNoV persists on 
fomites even after cleaning and transmission of HuNoV in healthcare settings is 
likely to occur even in the presence of interventions (71,20,31). Our models did 
not include any die off of HuNoV, which is justified by literature indicating 
persistence of HuNoVs on fomites well past the 24-hour time span examined in 
this work (72,69,73). However, our model also did not assume any additive effect 
from previous HuNoV source events, though this is likely to occur in real-world 
settings. We assumed that all HuNoV produced in the source event was 
infectious, when it is likely that a subset of measured HuNoVs are non-infectious 
particles. The recent development of a cell culture model for HuNoV represents 





We were unable to model all parameters using HuNoV-specific values and to 
separate out values for different HuNoV genotypes and genogroups. In 
particular, transfer rates for feces to hands during wipe were challenging to find 
in existing literature. Previous studies have addressed this by assuming a mass 
transfer of 0.1 g (75), while another study assumed a BetaPert distribution with a 
mode of 0.001 g feces, a minimum of 1 x 10-8 g, and a maximum of 1 x 10-1 g, 
though rationale for these values was not provided (42). When reported mass 
transfer from these studies was combined with our assumed mean stool weight 
of 98.2 g, the mode percent transfer of feces to hands was 0.1% (75) and 
0.001% (42). A third study measured transfer of the surrogate feline calicivirus 
(FCV) to hands from artificial feces and found that approximately 3% of virus was 
transferred in a high-contact scenario (76). These values result in feces to hand 
transfer rates that span four orders of magnitude. A similar variability was 
observed in literature on aerosolization of particles from a toilet flush. The 
generation rates calculated in this work were similar to that found by Johnson et 
al. (47) who estimated approximately 0.072 droplets forming for every 100 million 
particles; resulting in an aerosolization proportion of 1.3 x 10-10. However, 
another study estimated that between 33.3% and 60% of the total particles in a 
toilet rise above the toilet seat during a flush event (46). This results in possible 






This study adds to the growing body of literature that points to fomite 
transmission as a significant pathway in the spread of HuNoVs (77,72,78,73,79). 
We show that it is feasible for a single fomite contact to lead to a sizable risk of 
HuNoV infection in ESWs and that ESWs are able to transmit a significant 
amount of virus to secondary fomites, initiating further infections. Our work 
highlights the importance of studying ESWs as a unique population in healthcare 
settings, independent of clinical staff. ESWs are the first line of defense against 
healthcare associated infections, yet our understanding of the health risks they 
face remains minimal. This QMRA shows that ESWs likely face important 
occupational health risks from fomite-mediated infections and interventions are 
needed to both protect them and prevent further spread. Fomite cleaning and 
disinfection procedures should be designed in collaboration with ESWs and 
future work must focus on quantifying the risks posed to these essential workers. 
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Table 4.1 Model scenario by human norovirus source event, contact setting, and 
outcome 
 
























Table 4.2 Major assumptions of the models 
 
Assumptions Related to HuNoV Symptoms and Shedding 
 
All particles released from ill patient are initially infectious 
Source of virus is either bowel movements or vomit events – the patient does 
not passively shed 
 
Assumptions Related to Aerosolization of Viral Particles 
 
Bathroom door is closed during vomit/ diarrhea event 
Air mixing between rooms does not occur 
Air distribution of viral particles post flush and/ or post vomit event is uniform 
and occurs within 1 minute 
No aerosolization occurs directly from a diarrheal event 
 
Assumptions Related to Fomite Deposition of Viral Particles 
 
Virus in air does not settle on hands, it only deposits on fomites 
Deposition of virus from air to fomites occurs uniformly across the room 
 
Assumptions Related to Transfer of Viral Particles from Contact 
 
ESW cleans room once a day  
Virus does not inactivate in air or on fomites 
Transfer of virus from the hands of ill patient does not occur during vomit 
events and only results from wiping after a diarrhea event 
Transfer of viruses between fomites and hands is one directional - moving from 
fomite with high concentration to fomite with low concentration 
Distribution of virus is constant across touch area 





Assumptions Related to Calculated Fomite Concentration and Dose of 
HuNoV 
 
Contact between hand and mouth is done via single finger pad 
Only one hand to face contact event occurs before handwashing 








Table 4.3 Model parameter distributions and sources  
Description Units Distribution (values)a Truncation Typeb Source 
Virus shedding       
m.vv = mean 





Normal (1.6 x 105, 4.5 x 104) Min = 
2200  
Max = 1.2 
x 107 
U (40) 
c.vv = starting 
concentration of HuNoV 




BetaPert (2.2 x 103, m.vv, 1.2 x 107)  Min = 0 VU (41,42)  
m.vlv = mean volume of 
vomit in one event 




vl.v = volume of vomit in 
one event 
mL BetaPert (50, (m.vlv/2), 800) Min = 0 VU (40,80,43) 
m.mf = mean mass of 
feces from one event 




m.f = mass of feces from 
one event 
grams BetaPert (14.6, m.mf, 449.4) Min = 0 VU (45,44) 
c.vf = starting 





BetaPert (104,108,1010) Min = 104 
Max = 1.6 
x 1012 
V (17,81,42) 




p.av= proportion of virus 
particles released into air 
during vomit event 
proportion Low titer (c.vv < 1010):  
Normal (2.8 x 10-5, 1 x 10-5)  
 
High titer (c.vv ≥ 1010):  
Normal (1.3 x 10-4, 1 x 10-4) 
Min = 0  
Max = 1 
V (65,43) 
p.af = proportion of virus 
particles released into air 
during flush  
proportion Normal (2.42 x 10-7, 6.91 x 10-8) Min = 0  
Max = 1 
V (48) 
vlr = volume of room m3 Bathroom (s1a, s1b, s2a, s2b): 12.4 
Patient Room (s3a, s3b, s4a, s4b): 26.5 
 
- V (51,49,50) 
c.va = concentration of 
virus in room air  
virus particles/ 
m3  
Vomit in Bathroom, Immediately Post Flush 
(s1a, s1b) 
(c.vv * vl.v * (p.av + p.af)) / vlr 
 
Diarrhea in Bathroom, Immediately Post 
Flush (s2a, s2b) 
(c.vf * m.f * p.af) / vlr  
 
Vomit in Patient Room, Immediately After 
Event (s3a, s3b) 
(c.vv * vl.v * p.av) / vlr 
 




Diarrhea in Patient Room, Immediately 
After Event (s4a, s4b) 
0 
 
Fomite deposition      
delt.t = time between 
event and HCW fomite 
contact  
minutes Uniform (1,1440) - V Assumed 
s.as = virus settling rate 
from air to fomite during 
total time since event 
proportion/ m2 ≤ 30 minutes since event: 0.031 * delt.t 
> 30 minutes since event: 1 
- V (48) 
ah = area of hand that 
contacts fomite 
m2 0.001268 - 0 This study 
af = area of finger pad  m2 Uniform(0.000256, 0.0004) - V (54,58) 
r.fh = ratio between area 
of hand touch area and 
finger pad 
m2 af / ah - - Calculated 
Transfer Efficiencies       
t.fh = proportion of feces 
transferred to hands 
during wiping 
proportion BetaPert (10-10, 10-6, 10-3)  Min = 0 
Max = 1 
V (42,75,76) 
t.hs = transfer of virus 
particles from hand to 
fomite 
proportion Normal (0.15, 0.16) Min = 0  





t.sh = transfer of virus 
particles from fomite to 
hand 
proportion Normal (0.26, 0.19) Min = 0 
Max = 1 
V (55) 
t.hm = transfer between 
hand and mouth 
proportion Normal (0.34, 0.25) Min = 0 
Max = 1 
V (56-59) 
Fomite and Hand 
Concentrations 
     
c.vs = concentration of 
virus particles on contact 
area at time t 
virus particles Vomit in Bathroom, Immediately Post Flush 
(s1a, s1b) 
s.as * c.va * ah 
 
Diarrhea in Bathroom, Immediately Post 
Flush (s2a, s2b) 
(s.as * c.va * ah) + (m.f * t.fh * c.vf * t.hs) 
 
Vomit in Patient Room, Immediately After 
Event (s3a, s3b) 
s.as * c.va * ah 
 
Diarrhea in Patient Room, Immediately 
After Event (s4a, s4b) 
m.f * t.fh  * c.vf * t.hs 
 
 - - Calculated 
c.vh = concentration of 
virus on ESW hands 




c.v2s = concentration of 
norovirus on secondary 
contact fomite 
virus particles c.vh * t.hs - - Calculated 
Dose      
D = dose of virus 
ingested from primary 
fomite contact 
particles c.vh * r.hf * t.hm - - Calculated 
D2 = dose of virus 
ingested from secondary 
fomite contact 
virus particles c.vs2 * t.sh * r.hf * t.hm - - Calculated 
Dose response      
n = dose response 
constant 
 - 0.00255 - - (61,18) 
r = dose response 
constant 
 - 0.086 - - (61,18) 
risk.ill = risk of illness as 
a function of dose 
risk 1 - (1 + n*dose))^-r   - - (61,18) 
a Distribution types and values: Normal (mean, sd); BetaPert (minimum, mode, maximum); Uniform (minimum, 
maximum); Empirical (observed values)   
bU indicates uncertainty distribution, V indicates variability distribution, U + V is distributions with both an 





Table 4.4 Human norovirus infection risk for each scenario  
Scenario 
Median Risk of Illness 













4.18 x 10-5 
(1:23,928) 
(3.32 x 10-5, 
5.02 x 10-5) 
1.40 x 10-
14 
1.15 x 10-3 
1b 
8.54 x 10-6 
(1:117,104) 
(6.50 x 10-6, 
1.07 x 10-5) 
< 1 x 10-16 6.02 x 10-4 
2a 
3.46 x 10-1 
(1:3) 
(3.38 x 10-1, 
3.53 x 10-1) 
1.80 x 10-
14 
6.84 x 10-1 
2b 
2.35 x 10-1 
(1:4) 
(2.27 x 10-1, 
2.41 x 10-1) 
< 1 x 10-16 6.69 x 10-1 
3a 
1.94 x 10-5 
(1:51,504) 
(1.54 x 10-5, 
2.33 x 10-5) 
6.27 x 10-
15 
5.36 x 10-4 
3b 
3.97 x 10-6 
(1:252,185) 
(3.02 x 10-6, 
4.97 x 10-6) 
< 1 x 10-16 2.80 x 10-4 
4a 
3.46 x 10-1 
(1:3) 
(3.38 x 10-1, 
3.53 x 10-1) 
1.79 x 10-
14 
6.84 x 10-1 
4b 
2.35 x 10-1 
(1:4) 
(2.27 x 10-1, 
2.41 x 10-1) 






Figure 4.1 Conceptual exposure model for human norovirus transmission in 
each scenario  
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Chapter 4 Supplementary Material: R Code for Quantitative Microbial Risk 
Assessment 
 






































# VIRUS SHEDDING----------------- 
#m.vv Mean conc virus in vomit (log particles per mL): 
m.vv <- mcstoc(rnorm, type="U", mean=160000, sd=45000, seed=seed, 
rtrunc=TRUE, linf=2200, lsup=12000000) 
 
# c.vv  Conc virus in vomit (particles/mL): 
c.vv <- mcstoc(rpert, type="VU", min=2200, mode=m.vv, max=12000000, 
seed=seed, rtrunc=TRUE, linf=0) 
   




m.vlv <- mcstoc(rnorm, type="U", mean=845, sd=226.7, seed=seed, 
                    rtrunc=TRUE, linf=500, lsup=1000) 
 
# vl.v Volume of vomit in one event (mL): 
vl.v <- mcstoc(rpert, type="VU", min=50, mode=(m.vlv/2), max=800, 
seed=seed, rtrunc=TRUE, linf=0) 
 
#mm.f.log Mean mass of feces in one event (g) 
m.mf <- mcstoc(rnorm, type="U", mean=98.2, sd=17.08, seed=seed, 
rtrunc=TRUE, linf=14.6, lsup=449.4) 
 
#m.f Mass of feces from one event (g) 
m.f <- mcstoc(rpert, type="VU", min=14.6, mode=m.mf, max=449.4, 
seed=seed, rtrunc=TRUE, linf=0) 
 
#c.vf Concentration of virus in feces (partilces/ g) 
c.vf <- mcstoc(rpert, type="V", min=10000, mode=100000000, 




#p.av Proportion of virus particles released into air during vomit 
event (fraction): 




mean=(0.000028), sd=0.00001, seed=seed, rtrunc=TRUE, linf=0, lsup=1), 
                 mcstoc(rnorm, type="V", mean=0.00013, sd=0.0001, 
seed=seed, rtrunc=TRUE, linf=0, lsup=1)) 
   
# p.af Proportion of virus particles rleased into air during flush 
(fraction): 
p.af <- mcstoc(rnorm, type="V", mean=0.000000242,  sd=0.0000000691, 
seed=seed, rtrunc=TRUE, linf=0, lsup=1)  
 
#vl.r Total volume of room 
# vlr Total volume of bathroom (m^3) or patient room: 
 
#bathroom volume: 
vlr.12 <- mcdata(12.4, type="0") 
 
#pt room (3a, 3b, 4a, 4b) 
vlr.34 <- mcdata(26.5, type="0") 
 
# c.va Concentration of virus in bathroom air (particles/ m^3) 
#Vomit in Bathroom, Immediately Post Flush (s1a, s1b) 
c.va1 <- (c.vv * vl.v * (p.av + p.af)) / vlr.12 
 
#Diarrhea in Bathroom, Immediately Post Flush (s2a, s2b) 





#Vomit in Patient Room, Immediately After Event (s3a, s3b) 
c.va3 <- (c.vv * vl.v * p.av)/ vlr.34 
 
#SURFACE DEPOSITION --------------------- 
# delt.t Time between vomit event and HCW door knob contact (minutes): 
delt.t <- mcstoc(runif, type = "V", min = 1, max = 1440, seed=seed, 
rtrunc=TRUE, linf=0) 
 
# s.as Virus settling rate from air to surfaces (fraction of particles 
in m^3/ m^2/ minute): 
s.as <-  ifelse(delt.t<31, mcdata(0.031*delt.t, type="V"), mcdata(1, 
type="0")) 
 
# ah Area touched by hand (m^2): 
ah <-  mcdata(0.001268, type="0") 
 
#af Area of finger pad: 
af <- mcstoc(runif, type="V", min=0.000256, max=0.0004, seed=seed) 
 
#r.hf ratio of fingerpad to hand 
r.fh <- af/ah 
 




#t,fh Transfer of feces to hand after wipe 
t.fh <- mcstoc(rpert, type="V", min=0.0000000001, mode=0.000001, 
max=0.001, seed=seed, rtrunc=TRUE, linf=0, lsup=1) 
 
#t.hs Transfer efficiency from hand to surface 
t.hs <- mcstoc(rnorm, type = "V", mean=0.15, sd=0.16, seed=seed, 
rtrunc=TRUE, linf=0, lsup=1) 
 
#t.sh Transfer efficient from surface to hand 
t.sh <- mcstoc(rnorm, type="V", mean=0.26, sd=0.19, seed=seed, 
rtrunc=TRUE, linf=0, lsup=1) 
 
#t.hm  Transfer efficiency between hand and mouth (fraction): 
t.hm <- mcstoc(rnorm, type="V", mean=0.34, sd=0.25, seed=seed, 
rtrunc=TRUE, linf=0, lsup=1) 
 
   
#SURFACE and HAND CONCENTRATIONS---------------- 
# c.vs Particles on door handle at time t (particles) 
#1a, 1b: Vomit in Bathroom, Immediately Post Flush  
c.vs1 <- (s.as * c.va1 * ah) 
   
#2a, 2b: Diarrhea in Bathroom, Immediately Post Flush  




   
#3a, 3b: Vomit in Patient Room, Immediately After Event 
c.vs3 <- s.as * c.va3 * ah 
   
#4a, 4b: Diarrhea in Patient Room, Immediately After Event  
c.vs4 <- m.f * t.fh  * c.vf * t.hs 
 
# ALL c.vh Concentration of virus on hands (particles/ hand): 
c.vh1 <- c.vs1 * t.sh 
c.vh2 <- c.vs2 * t.sh 
c.vh3 <- c.vs3 * t.sh 
c.vh4 <- c.vs4 * t.sh 
 
#c.v2s Concentration of virus on secondary contact surface (ie. ward 
door) 
c.v2s1 <- c.vh1 * t.hs 
c.v2s2 <- c.vh2 * t.hs 
c.v2s3 <- c.vh3 * t.hs 
c.v2s4 <- c.vh4 * t.hs 
 
#DOSE--------------------------- 
# D Dose of virus ingested by ESW: 
D1 <- c.vh1 * r.fh * t.hm 




D3 <- c.vh3 * r.fh * t.hm 
D4 <- c.vh4 * r.fh * t.hm 
 
# Dsec Dose of virus ingested by secondary contact on ward: 
Dsec1 <- c.v2s1 * t.sh * r.fh * t.hm 
Dsec2 <- c.v2s2 * t.sh * r.fh * t.hm 
Dsec3 <- c.v2s3 * t.sh * r.fh * t.hm 
Dsec4 <- c.v2s4 * t.sh * r.fh * t.hm 
   
# Dose response constants - using Miranda 2018 paper 
n <- mcdata(0.00255, type="0") 
r <- mcdata (0.086, type="0") 
risk.ill.1a <- 1 - (1+(n*D1))^(-r) 
risk.ill.2a <- 1 - (1+(n*D2))^(-r) 
risk.ill.3a <- 1 - (1+(n*D3))^(-r) 
risk.ill.4a <- 1 - (1+(n*D4))^(-r) 
 
risk.ill.1b <- 1 - (1+(n*Dsec1))^(-r) 
risk.ill.2b <- 1 - (1+(n*Dsec2))^(-r) 
risk.ill.3b <- 1 - (1+(n*Dsec3))^(-r) 
risk.ill.4b <- 1 - (1+(n*Dsec4))^(-r) 
   
#mc ---------------------- 




t.sh, t.hm, vlr.12, 
            ah, af, r.fh, c.va1, c.vs1, c.vh1, D1, n, r, risk.ill.1a) 
 
s1b <- mc(m.vv, c.vv, m.vlv, vl.v, p.av, p.af, delt.t, s.as, t.hs, 
t.sh, t.hm, vlr.12, 
          ah, af, r.fh, c.va1, c.vs1, c.vh1, c.v2s1, Dsec1, n, r, 
risk.ill.1b) 
 
s2a <- mc(m.mf, m.f, c.vf, p.af, vlr.12, c.va2, delt.t, s.as, ah, af, 
r.fh,  
          t.fh, t.hs, t.sh, t.hm, c.vs2, c.vh2, D2, n, r, risk.ill.2a) 
 
s2b <- mc(m.mf, m.f, c.vf, p.af, vlr.12, c.va2, delt.t, s.as, ah, af, 
r.fh,  
          t.fh, t.hs, t.sh, t.hm, c.vs2, c.vh2, c.v2s2, Dsec2, n, r, 
risk.ill.2b) 
 
s3a <- mc(m.vv, c.vv, m.vlv, vl.v, p.av, delt.t, s.as, t.hs, t.sh, 
t.hm, vlr.34, 
           ah, af, r.fh, c.va3, c.vs3, c.vh3, D3, n, r, risk.ill.3a) 
 
s3b <- mc(m.vv, c.vv, m.vlv, vl.v, p.av, delt.t, s.as, t.hs, t.sh, 
t.hm, vlr.34, 






s4a <- mc(m.mf, m.f, c.vf, ah, af, r.fh, t.fh, t.hs, t.sh, t.hm, 
           c.vs4, c.vh4, D4, n, r, risk.ill.4a) 
 
s4b <- mc(m.mf, m.f, c.vf, ah, af, r.fh, t.fh, t.hs, t.sh, t.hm, 





#S1A: vomit in bathroom, ESW gets sick ---------------- 
summary(s1a$risk.ill.1a) 
tors1a <- tornado(s1a) 
s1a.tor <- as.data.frame(print(tors1a)[[1]]) 
 
#S1B: vomit in bathroom, ESW spreads to ward---------------- 
summary(s1b$risk.ill.1b) 
tors1b <- tornado(s1b) 
s1b.tor <- as.data.frame(print(tors1b)[[1]]) 
 
#S2A: diarrhea in bathroom, ESW gets sick---------------- 
summary(s2a$risk.ill.2a) 




tors2a <- tornado(s2a) 
s2a.tor <- as.data.frame(print(tors2a)[[1]]) 
 
#S2B: diarrhea in bathroom, ESW spreads to ward---------------- 
summary(s2b$risk.ill.2b) 
tors2b <- tornado(s2b) 
s2b.tor <- as.data.frame(print(tors2b)[[1]]) 
 
#S3A: vomit in room, ESW gets sick---------------- 
summary(s3a$risk.ill.3a) 
tors3a <- tornado(s3a) 
s3a.tor <- as.data.frame(print(tors3a)[[1]]) 
 
#S3B: vomit in room, ESW spreads to ward---------------- 
summary(s3b$risk.ill.3b) 
tors3b <- tornado(s3b) 
s3b.tor <- as.data.frame(print(tors3b)[[1]]) 
 
#S4A: diarrhea in room, ESW gets sick---------------- 
summary(s4a$risk.ill.4a) 
tors4a <- tornado(s4a) 
s4a.tor <- as.data.frame(print(tors4a)[[1]]) 
 





tors4b <- tornado(s4b) 






Conclusions, Public Health Significance,  
and Future Directions 
 
Microbial infections place a significant health burden on society and are an 
important area of research. In particular, diarrheal illnesses kill thousands of 
people ever year, the majority of whom are children under the age of five (1,2). 
The leading cause of these diarrheal illnesses is human norovirus (HuNoV) 
which in one year will kill 200,000 people, infect 685 million, and cost the global 
economy $64.5 billion (3-5). This extremely infectious virus has no specific 
treatment or vaccine (5). In absence of medical interventions, engineering and 
behavior controls to prevent HuNoV are necessary. Many of these controls 
require measuring or modeling the presence of HuNoV in the environment as a 
means to target interventions, measure efficacy of disinfection, or predict health 
threats with risk assessments (6-8). However, since the first documentation of a 
HuNoV outbreak in 1968, the study and prevention of these viruses has been 
significantly impeded by an inability to grow HuNoV in any known laboratory cell 
line (9,10). With the lack of a cell culture model for infectivity, HuNoV detection 
has relied solely on detection of viral RNA using molecular tools, predominately 
by the use of reverse transcription-quantitative polymerase chain reaction (RT-




viral copy numbers has been used to infer viral levels. Though these molecular 
methods are rapid, sensitive, and easily quantifiable, they remain unable to 
provide an accurate measure of infectious HuNoV as GE only represent the 
target nucleic acid segment that was amplified by RT-PCR (10). GE cannot be 
used to determine the infectious nature of isolated virus which limits the value 
when focusing on public health outcomes. 
 
The development of the first reproducible method for culturing HuNoV in vitro 
was reported in 2016 which revolutionized the study of HuNoV (12). This novel 
cell culture method uses human intestinal enteroids (HIEs) which are 3D cultures 
that recapitulate the human intestinal epithelium (12,13). To date, researchers 
have applied this HIE culture approach to make strides in our knowledge of the 
physiology of HuNoV infections, in vaccine development, and in improved clinical 
detection (14-18,12,19,20). Another important area of HuNoV research that can 
benefit from the HIE method is environmental monitoring applications. This 
includes identifying the virus in food, water, air, and on fomites in order to predict 
human health risk and inform interventions. It is important to note that although 
the HIE approach can identify infectious viruses present in a sample, there is still 
the need to integrate RT-qPCR GE measurements for data output. This is done 
by comparing GE at one-hour post infection to 72-hours post infection via RT-




infectivity outcomes which include plaque assays or most probable number 
(MPN) estimates using cytopathic effects.   
 
To date, most applications of the HIE method for culturing HuNoV have been 
focused on clinical applications (14,17,19,20). Adaptation of the HIE method to 
environmental monitoring efforts for HuNoV poses a unique set of challenges 
compared to existing work using HIEs. The goal of this dissertation was to 
address some of these challenges and build a foundation for applying the HIE 
model in environmental monitoring scenarios. This was achieved through three 
specific research aims: (1) establish a set of research-based methodological 
recommendations for environmental sampling applications of the HIE system, (2) 
pilot the HIE system for surface recovery of HuNoV, and (3) develop a 
quantitative microbial risk assessment (QMRA) that can be a template for 
translating infectious HuNoV data from HIEs to public health interventions. 
 
The first of these research goals was described in Chapter 2, “Optimizing human 
intestinal enteroids for environmental monitoring of human noroviruses.” In this 
chapter, I systematically examined six experimental variables of the HIE HuNoV 
assay: HIE age, HIE monolayer basement membrane, HuNoV inoculum 
processing, HuNoV inoculum volume, handling of data below limit of detection 
(LOD), and cutoff for positive samples. I found that HIEs were able to 




that were examined: passage out to 58, 187 days of continuous growth, and after 
334 days of enteroids archived in liquid nitrogen. Basement membrane and 
HuNoV processing methods were not associated with a change in HuNoV 
replication in HIEs. Higher inoculum volumes did not impact qualitative detection 
of infectious HuNoV and volumes close to the well maximum (250 microliters per 
well) are suggested to facilitate testing of larger volume samples in 
environmental applications. This finding will be incredibly valuable when 
examining low levels of virus present in many environmental locations. LOD 
replacement and fold cutoff values affected the qualitative measure of infectious 
HuNoV and should be explicitly stated in future work. This chapter also 
presented a list of data-informed best practices for experimental variables for the 
cultivation of HuNoV in HIEs, including a survey of current practices in the 
literature. The recommendations from this chapter can inform future applications 
of the HIE system for growing HuNoV, particularly those with the goal of 
environmental monitoring.  
 
The second research aim was addressed in Chapter 3: “Recovery of infectious 
human noroviruses from fomites via replication in intestinal enteroids.” This work 
applied the HuNoV HIE cell culture method to measure infectious HuNoV 
recovered from fomites. Three fomites — a laminate hospital bed tray, a metal 
door handle, and a plastic sanitizer dispenser — were inoculated with HuNoV 




cultivation of fomite-recovered HuNoV in HIEs occurred from surfaces inoculated 
with at least 105 HuNoV GE/ cm2. The highest recovery of infectious HuNoV was 
from surfaces inoculated with a high viral titer (>106 GE) in 50μL of inoculum. No 
difference was observed in recovery of infectious HuNoV across the three 
fomites. This is promising for future environmental monitoring work as it appears 
that multiple types of fomites can be swabbed for infectious HuNoV. Of note, I 
found that even in scenarios with low molecular recovery of HuNoV RNA 
(<0.1%), infectious HuNoV particles could still be collected from fomites and 
grown in HIEs. In a subset of swabbing experiments, I also tested recovery of the 
surrogate virus MS2 coliphage. MS2 have been used as HuNoV surrogates for 
decades and including this surrogate while developing a new approach is 
standard practice (21,22).  Recovery of MS2 was comparable between molecular 
and infectivity methods, which provides validity to my experimental set-up. MS2 
recovery (74%) was 2-fold greater than molecular HuNoV recovery (0.74%), 
which is consistent with previous evidence that MS2 inactivation may not be 
comparable to HuNoV inactivation (21-23,10,24-26). Literature has suggested 
that MS2 may be more resistant to inactivation than HuNoV which can be 
protective of human health but may overestimate inactivation needs, leading to 
waste of resources (23). HIEs will grow fomite-recovered HuNoV and 
inconsistency in results obtained with the surrogate virus MS2, compared to 
those obtained for HuNoV in HIEs, further justify the time and effort required to 




work offers an approach to move forward with fomite monitoring and disinfection 
studies.  
 
The third research aim of this dissertation was addressed in Chapter 4: 
“Quantitative microbial risk assessment of human norovirus infection in 
environmental service workers due to healthcare-associated fomites.” In this 
chapter I developed a quantitative microbial risk assessment (QMRA) looking at 
HuNoV infection risks from fomite contacts posed to environmental service 
workers (ESWs) in healthcare settings. For a single fomite contact in a room 
where a patient experienced a diarrhea event, the risk of HuNoV infection for 
ESWs was as high as 1:3. For scenarios where the ill patient vomited without a 
diarrheal event, the estimated risk to ESWs from one fomite contact dropped 
significantly – to 1:23,928 for an in-bathroom event and 1:51,504 for an in-room 
event. For secondary HuNoV infection from contact with a contaminated fomite, 
risks were 32% lower than ESW infection risks in diarrhea scenarios and 80% 
lower than ESW infection risks in vomit scenarios. The high risk estimates in 
diarrhea scenarios indicate that transmission of HuNoV from diarrhea may be 
primarily driven by fomite transfer, as compared to airborne or person-to-person 
transfer from vomit events. I demonstrated that a single fomite contact event can 
lead to high infection risk in ESWs and that ESWs may be able to spread HuNoV 
to other ward surfaces and initiate secondary infections. This study adds to the 




pathway in the spread of HuNoVs (27-31). ESWs likely face important 
occupational health risks from fomite-mediated infections and interventions are 
needed to both protect them and prevent further spread.  
 
Taken together, the research presented in this dissertation provides a strategy 
for using the HIE system to cultivate HuNoV recovered from the environment and 
presents a QMRA model that can be integrated with future measures of 
infectious HuNoV. The main limitations of this work are ongoing challenges with 
the HIE method for HuNoV cultivation and low data availability for constructing 
QMRA models. For chapters 2 and 3, the inability to directly quantify HuNoV 
grown in HIEs makes comparisons challenging and prevents the calculation of 
percent recovery. In the future, methods to quantify HuNoV growth in HIEs 
should be explored, such as the MPN method. For Chapter 4, much of the data 
required for the QMRA was not explicitly available and multiple assumptions had 
to be made. Additionally, the data used for the QMRA was not norovirus specific 
in many cases and instead was pulled from literature on other pathogens or 
surrogate viruses. 
 
This work contributes a number of novel findings to the body of HuNoV literature. 
In Chapter 2, I investigated a series of methodological variables in the HIE 
system and their impact on HuNoV growth. This work is the first to examine HIE 




LOD handling, and choice of fold cutoff and offers a set of evidence-based 
recommendations that can improve the use of the HIE system to grow HuNoV. In 
Chapter 3, I demonstrated that HuNoV can be recovered from fomites and 
successfully grown in HIEs. This is the first work to use the HIE system with 
fomite recovered viruses and serves as a foundation for future work on growing 
HuNoV recovered from the environment. Finally, Chapter 4 presented a QMRA 
of HuNoV infection risk from fomites posed to ESWs. This QMRA is the first to 
examine these specific scenarios and serves to enhance the literature on HuNoV 
and healthcare QMRAs. The model I produced in Chapter 4 is a template for 
future QMRAs and provides a framework to integrate HuNoV infectivity data from 
HIEs in the future. 
 
HuNoV poses a significant health burden and leads to a large number of 
illnesses, loss of life, and substantial economic losses. This dissertation 
addressed one of the main challenges in HuNoV research – the inability to 
culture HuNoV in vitro. The development of the technique to grow HuNoV in HIEs 
opened the door for new research that could better relate HuNoV detection to 
infectious viruses and, ultimately, health outcomes. This body of work 
demonstrates how the HIE cell culture can be used in environmental detection of 
HuNoV moving forward. Through the development of methods, application of 




HIE method to translate measurement of infectious HuNoV from the lab bench to 
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